US5595976A - Tetrahydropyran compounds - Google Patents

Tetrahydropyran compounds Download PDF

Info

Publication number
US5595976A
US5595976A US08/521,189 US52118995A US5595976A US 5595976 A US5595976 A US 5595976A US 52118995 A US52118995 A US 52118995A US 5595976 A US5595976 A US 5595976A
Authority
US
United States
Prior art keywords
optionally substituted
mmol
carbon atoms
branched
isopropylidene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/521,189
Inventor
David Billington
Gilbert Dorey
Pascale Leon
Ghanem Atassi
Alain Pierre
Michael Burbridge
Nicolas Guilbaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADIR SARL
Original Assignee
ADIR SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADIR SARL filed Critical ADIR SARL
Assigned to ADIR ET COMPAGNIE reassignment ADIR ET COMPAGNIE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ATASSI, GHANEM, BILLINGTON, DAVID, BURBRIDGE, MICHAEL, DOREY, GILBERT, GUILBAUD, NICOLAS, LEON, PASCALE, PIERRE, ALAIN
Application granted granted Critical
Publication of US5595976A publication Critical patent/US5595976A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Definitions

  • the present invention relates to new glucidic compounds having a tetrahydropyran structure, to a process for the preparation thereof, and to pharmaceutical compositions containing them.
  • the compounds of the present invention are highly valuable for therapeutic use on account of their angiogenesis-inhibiting ability.
  • Angiogenesis (or neovascularisation) is defined as the development and growth of new capillary blood vessels.
  • the process of angiogenesis is essential in many physiological situations including the development of the embryo, the normal healing of injuries and the development of the endometrium after menstruation. Apart from those situations, angiogenesis in normal adults is very rare and the mitosis of the endothelial cells which produces the walls of the blood vessels is very slow, with cell renewal times which are measured in years.
  • Abnormal angiogenesis (that is to say, stimulation of the growth of new blood vessels owing to a pathological syndrome) is an established characteristic of many diseases, especially diabetic retinopathy, rheumatoid arthritis, haemangioma and the growth of solid tumours.
  • Angiogenesis can also play an important part in other diseases, such as arterio-coronary disease.
  • compositions can, therefore, stop the growth of primary tumours, prevent or reduce the formation of metastases, and prevent the appearance of secondary growths.
  • angiogenesis inhibitors are also useful in the treatment of non-neoplasic diseases mentioned above in which angiogenic activity occurs.
  • the present invention relates to new compounds that have a tetrahydropyran structure and that are structurally and pharmacologically original as compared with the compounds described in the prior art.
  • the present invention relates to compounds of the general formula (I): ##STR2## in which: A - either represents --OR 6 , and B represents --CH 2 --X,
  • R 1 - either represents the radical: ##STR3## in which Y and Z either each represent hydrogen or together form a double bond or together form, with the carbon atoms carrying them, an oxirane ring,
  • R 2 is selected from hydrogen, a hydroxy radical and the radical --OR 9 ,
  • n is an integer from 1 to 4 inclusive and Y and Z either each represent hydrogen or together form a double bond or together form, with the carbon atoms carrying them, an oxirane ring,
  • R 2 represents hydrogen
  • R 3 is selected from hydrogen, a linear or branched, optionally substituted alkyl radical having from 1 to 6 carbon atoms, an optionally substituted benzyl radical, an optionally substituted benzoyl radical, an optionally substituted formyl radical, a linear or branched, optionally unsaturated and optionally substituted acyl radical having from 1 to 6 carbon atoms, an allyl radical, and an optionally mono- or di-substituted carbamoyl radical,
  • R 4 - either is selected from a hydroxy radical, a linear or branched, optionally substituted alkoxy radical having from 1 to 6 carbon atoms, an optionally mono- or di-substituted carbamoyloxy radical, a piperazinylcarbonyloxy radical substituted in the 4-position by the radical R 9 , and an imidazol-1-ylcarbonyloxy radical, and R 5 represents hydrogen,
  • R 6 , R 7 and R 8 are selected, each independently of the others, from hydrogen, a linear or branched, optionally substituted alkyl radical having from 1 to 6 carbon atoms, and a phenylalkyl radical in which the phenyl group is optionally substituted and the alkyl group, which is linear or branched and is optionally substituted, has from 1 to 6 carbon atoms,
  • R 9 is selected from hydrogen, a linear or branched, optionally substituted alkyl radical having from 1 to 6 carbon atoms, an optionally substituted formyl radical, a linear or branched, optionally unsaturated and optionally substituted acyl radical having from 1 to 6 carbon atoms, a linear or branched, optionally substituted alkoxycarbonyl radical having from 1 to 6 carbon atoms, an optionally substituted benzyl radical, and an optionally mono- or di-substituted carbamoyl radical,
  • X is selected from a hydroxy radical, a halogen atom, an optionally substituted phenylsulfonyloxy radical, and an optionally substituted linear or branched alkylsulfonyloxy radical having from 1 to 6 carbon atoms,
  • radicals may be substituted by one or more chemical entities selected from hydroxy, halogen, trihalomethyl, amino, alkylamino, dialkylamino, linear or branched alkoxy having from 1 to 6 carbon atoms, linear or branched alkoxycarbonyl having from 1 to 6 carbon atoms, and linear or branched acyl having from 1 to 6 carbon atoms,
  • alkylsulfonyloxy and phenylsulfonyloxy radicals indicates that those radicals may be substituted by one or more linear or branched alkyl radicals having from 1 to 6 carbon atoms, and
  • carbamoyl radical is to be understood as meaning the radical ##STR6## and carbamoyloxy radical is to be understood as meaning the radical ##STR7##
  • acids that can be used for the formation of pharmaceutically acceptable salts there may be mentioned, by way of non-limiting example, hydrochloric acid, phosphoric acid, sulfuric acid, tartaric acid, citric acid, maleic acid, fumaric acid, etc..
  • the present invention relates also to a process for the preparation of a compound of formula (I), characterised in that 1,2:4,5-di-O-isopropylidene- ⁇ -D-fructopyranose of formula (II): ##STR8## prepared in accordance with the procedure described by E. J. Prisbe et al. (J. Org. Chem., 41, (1976), 1836-1846), is subjected
  • R 7 and R 8 are selected, each independently of the other, from hydrogen, a linear or branched, optionally substituted alkyl radical having from 1 to 6 carbon atoms, and a phenylalkyl radical in which the phenyl group is optionally substituted and the alkyl group, which is linear or branched and is optionally substituted, has from 1 to 6 carbon atoms,
  • R 7 and R 8 are as defined above, which may optionally be subjected to the action of an alkyl halide, an acyl halide, a benzyl halide, an alkyl haloformate or an isocyanate in order to yield the compound of formula (Va 2 ): ##STR12## in which R 7 and R 8 are as defined above and R' 9 is selected from a linear or branched, optionally substituted alkyl radical containing from 1 to 6 carbon atoms, an optionally substituted formyl radical, an optionally substituted acyl radical containing from 1 to 6 carbon atoms, an optionally substituted benzyl radical, a linear or branched, optionally substituted alkoxycarbonyl radical containing from 1 to 6 carbon atoms, and an optionally mono- or di-substituted carbamoyl radical,
  • R 2 is selected from hydrogen, a hydroxy radical and the radical --OR 9 ,
  • n is an integer from 1 to 4 inclusive and R 7 , R 8 , Y and Z are as defined above,
  • R 2 represents hydrogen
  • R 2 represents the radical: ##STR25## as defined above, and R 3 is as defined above,
  • an isocyanic compound in the presence or absence of an activator, such as 4-dimethylaminopyridine,
  • R 1 , R 2 , R 3 , R 4 and R 5 are as defined above and R' 6 is selected from a linear or branched, optionally substituted alkyl radical having from 1 to 6 carbon atoms, and a phenylalkyl radical in which the phenyl group is optionally substituted and the alkyl group, which is linear or branched and is optionally substituted, has from 1 to 6 carbon atoms,
  • the compound of formula (Va 1 ) in which R 7 represents hydrogen can advantageously be obtained by reaction of an organolithium compound, prepared from the corresponding propargyl compound, of formula (IVa'): ##STR37## in which R 8 is as defined above, then by catalytic hydrogenation of the resulting alkyne of formula (Va 1 '): ##STR38## in which R 8 is as defined above.
  • the compound of formula (VIII) can be protected regioselectively in the form of a silylated compound of formula (VIII'): ##STR39## in which R 1 and R 2 are as defined above and R a , R b and R c each independently of the others represent a linear or branched alkyl radical containing from 1 to 6 carbon atoms, or a phenyl radical.
  • the compounds of formula (I) have valuable pharmacological properties.
  • the compounds are powerful angiogenesis inhibitors which have the advantage of being much less toxic as compared with the reference compounds. They therefore have an excellent therapeutic index.
  • the compounds can be used in therapeutics as anti-tumour agents, in the inhibition of the formation and growth of metastases, as well as in the treatment of diabetic retinopathy, rheumatoid arthritis, haemangioma and arterio-coronary diseases, and more generally in disorders due to or associated with angiogenesis disorders.
  • the present invention relates also to pharmaceutical compositions comprising the compounds of formula (I), their stereoisomers, where appropriate, or, where appropriate, their pharmaceutically acceptable addition salts with an acid, on their own or in combination with one or more inert, non-toxic excipients or carriers.
  • compositions according to the invention there may be mentioned more especially those which are suitable for oral, parenteral, nasal, rectal, perlingual, ocular or respiratory administration, especially tablets, dragees, sublingual tablets, sachets, paquets, gelatin capsules, glossettes, lozenges, suppositories, creams, ointments, dermic gels, injectable or drinkable preparations, aerosols, ocular or nasal drops.
  • the dosage used varies according to the age and weight of the patient, the mode of administration and the nature of the therapeutic indication and of any associated treatments, and ranges from 0.01 to 1 g per day, in one or more administrations.
  • Step A 1,2:4,5-di-O-isopropylidene- ⁇ -n-erythro-2,3-hexodiulo-2,6-pyranose
  • reaction mixture is stirred at 10° C. for 5 hours and is then concentrated (to 5 ml ) in vacuo. 30 ml of diethyl ether are added and the whole is filtered. The filtrate is then evaporated and the resulting solid residue is chromatographed on silica gel (eluant: ethyl acetate/pentane, 3:2). 0.81 g (3.14 mmol) of the desired product in the form of a white-coloured solid is isolated.
  • Step B 1,2:4,5-di-O-isopropylidene-3-isopropenyl- ⁇ -D-psicopyranose
  • reaction mixture After 45 minutes' stirring at -78° C., the reaction mixture is poured into a 10% aqueous ammonium chloride solution (40 ml) cooled to 0° C. The whole is diluted with diethyl ether (100 ml) and the reaction mixture is extracted. Customary treatment of the organic phase yields an oily residue, which is chromatographed on silica gel (eluant: pentane/ethyl acetate, 8:1). 0.55 g (1.83 mmol) of the desired product is obtained in the form of a white foam.
  • Step C 1,2-O-isopropylidene-3-isopropenyl- ⁇ -D-psicopyranose
  • the solvents are evaporated off under reduced pressure, the residue is taken up in 50 ml of toluene, and then evaporation is carried out again. That operation is repeated twice to yield, after 24 hours' drying under a high vacuum, 3.28 g (12.60 mmol) of the desired compound (purity >99% by gas chromatography) in the form of a white-coloured powder.
  • This compound is obtained in a manner identical to that described in Example 4, starting from 0.20 g (0.60 mmol) of the compound obtained in the preceding Example, 0.15 g (1.78 mmol) of solid sodium hydrogen carbonate and 0.22 g (0.93 mmol) of 72% 3-chloroperbenzoic acid.
  • Example 5 Following the procedure described for the preparation of Example 5, starting from 1.20 g (4.37 mmol) of the compound obtained in Example 2 and 0.96 g (6.52 mmol) of benzoyl isocyanate, and after purification by chromatography on silica gel (eluant: diethyl ether/methylene chloride, 2:1), 1.30 g (3.08 mmol) of the desired product are obtained.
  • Example 4 Following the procedure described for the preparation of Example 4, starting from 0.25 g (0.59 mmol) of the compound obtained in Example 7 and 0.22 g (0.93 mmol) of 72% 3-chloroperbenzoic acid, then purification by chromatography on silica gel (eluant: diethyl ether/heptane, 5:1), 0.10 g (0.23 mmol) of the desired compound in the form of a white-coloured foam is collected.
  • silica gel eluant: diethyl ether/heptane, 5:1
  • Example 10 1-(para-Toluenesulfonyl)-3-isopropenyl-4-O-methyl-5-O-methylcarbamoyl-.beta.-D-psicopyranose
  • Example 4 Following the procedure described for the preparation of Example 4, starting from 0.25 g (0.56 mmol) of the compound obtained in the preceding Example and 0.21 g (0.89 mmol) of 72% 3-chloroperbenzoic acid, then purification by chromatography on silica gel (eluant: pentane/ethyl acetate, 1:1), 0.16 g of the desired product in the form of a white-coloured foam is obtained.
  • 0.29 g (3.34 mmol) of lithium bromide is added at room temperature, in a single portion, to a solution of 0.31 g (0.69 mmol) of the compound obtained in Example 10 in 15 ml of acetone.
  • the reaction mixture is placed under stirring and then heated at 75° C. for 1.5 hours.
  • a further 0.26 g (2.99 mmol) of lithium bromide is then added and the whole is again heated at 75° C. for one hour.
  • the acetone is evaporated off under reduced pressure and the residue is taken up in 20 ml of ethyl acetate.
  • Customary treatment of the organic phase yields 0.23 g (0.65 mmol) of the desired product in the form of a white-coloured foam.
  • Example 4 Following the procedure described for the preparation of Example 4, starting from 0.23 g (0.65 mmol) of the compound obtained in the preceding Example and 0.23 g (0.97 mmol) of 72% 3-chloroperbenzoic acid, then purification by chromatography on silica gel (eluant: diethyl ether), 0.16 g (0.43 mmol) of the desired compound in the form of a white-coloured solid is obtained.
  • reaction mixture After 50 minutes' stirring at 0° C., the reaction mixture is poured into 100 ml of an aqueous ammonium chloride solution (10%) cooled to 0° C.
  • Customary treatment of the organic phase yields, after purification by chromatography on silica gel (eluant: pentane/ethyl acetate, 8:1 then 5:1), 2.93 g (10.16 mmol) of the desired product in the form of a yellow-coloured oil.
  • Example 4 Following the procedure described for the preparation of Example 4, starting from 0.44 g (1.52 mmol) of the compound obtained in Example 14 and 0.40 g (1.69 mmol) of 72% 3-chloroperbenzoic acid, then purification by chromatography on silica gel (eluant: pentane/ethyl acetate, 1.5:1), 0.27 g (0.89 mmol) of the desired compound in the form of a white-coloured solid is obtained.
  • Example 4 Following the procedure described for the preparation of Example 4, starting from 0.25 g (0.91 mmol) of the compound obtained in Example 2 and 0.34 g (1.44 mmol) of 72% 3-chloroperbenzoic acid, then purification by chromatography on silica gel (eluant: pentane/ethyl acetate, 2:1), 0.17 g (0.58 mmol) of the desired compound in the form of a white-coloured foam is obtained.
  • Example 17 1,2-O-Isopropylidene-2,5-hexodiulo-3-(2-methyloxiran-2-yl)-4-O-methyl-.beta.-D-erythro-2,6-pyranose
  • Example 22 4,5-di-O-Chloroacetylcarbamoyl-1,2-O-isopropylidene-3-isopropenyl- ⁇ -D-psicopyranose
  • Example 3 Following the procedure described for the preparation of Example 3, starting from 0.50 g (1.82 mmol) of the compound obtained in Example 1 and 0.50 ml (0.70 g; 5.87 mmol) of chloroacetyl isocyanate, then purification by chromatography on silica gel (eluant: ethyl acetate/pentane, 1:1), 0.90 g (1.80 mmol) of the desired product in the form of a white-coloured solid is obtained.
  • Example 4 Following the procedure described for the preparation of Example 4, starting from 0.30 g (0.60 mmol) of the product described in Example 22 and 0.17 g (0.72 mmol) of 72% 3-chloroperbenzoic acid, then purification by chromatography on silica gel (eluant: diethyl ether), 0.19 g (0.38 mmol) of the desired product in the form of a white-coloured foam is obtained.
  • Example 4 The title compound is obtained starting from the compound described in Example 2, in accordance with the procedure described in Example 3, by replacing chloroacetyl isocyanate with phenyl isocyanate and then carrying out the oxidation described in Example 4.
  • Step A 5-O-tert.butyldimethylsilyl-1,2-O-isopropylidene-3-isopropenyl-3,4-di-O-methyl- ⁇ -D-psicopyranose
  • Step B 1,2-O-isopropylidene-3-isopropenyl-3,4-di-O-methyl- ⁇ -D-psicopyranose
  • Example 3 Following the procedure described for the preparation of Example 3, starting from 0.10 g (0.35 mmol) of the compound obtained in Example 25 and 0.05 ml (0.07 g; 0.59 mmol) of chloroacetyl isocyanate, purification by chromatography on silica gel (eluant: diethyl ether) yields 0.14 g (0.34 mmol) of the desired product in the form of a white-coloured foam.
  • Example 4 Following the procedure described for the preparation of Example 4, starting frown 0.27 g (0.94 mmol) of the product described in Example 25 and 0.81 g (3.38 mmol) of 72% 3-chloroperbenzoic acid, then purification by chromatography on silica gel (eluant: diethyl ether), 0.25 g (0.82 mmol) of the desired product in the form of a white-coloured solid is obtained.
  • Example 3 Following the procedure described for the preparation of Example 3, starting from 0.23 g (0.75 mmol) of the product obtained in Example 27 and 0.08 ml (0.11 g; 0.94 mmol) of chloroacetyl isocyanate, then purification by chromatography on silica gel (eluant: methylene chloride/ethyl acetate, 4:1), 0.25 g (0.59 mmol) of the desired product in the form of a white-coloured foam is obtained.
  • silica gel eluant: methylene chloride/ethyl acetate, 4:1
  • Example 9 Following the procedure described for the preparation of Example 9, starting from 1.00 g (3.47 mmol) of the compound obtained in Example 14 and 25 g of acidic resin (DOWEX 50X8-100) heated in 50 ml of water, then purification by chromatography on silica gel (eluant: diethyl ether then ethyl acetate), 0.59 g (2.38 mmol) of the desired product in the form of a white-coloured solid is obtained.
  • acidic resin DOWEX 50X8-100
  • Example 10 Following the procedure described for the preparation of Example 10, starting from 0.80 g (3.22 mmol) of the compound obtained in Example 29 and 1.53 g of tosyl chloride in 15 ml of anhydrous pyridine, then purification by chromatography on silica gel (eluant: diethyl ether/pentane, 2:1), 0.92 g (2.28 mmol) of the desired product in the form of a white-coloured foam is obtained.
  • silica gel eluant: diethyl ether/pentane, 2:1
  • Example 12 Following the procedure described for the preparation of Example 12, starting from 0.10 g (0.25 mmol) of the compound obtained in Example 30 and 0.18 g (1.20 mmol) of sodium iodide in 3 ml of acetone at room temperature, then purification by chromatography on silica gel (eluant: diethyl ether/pentane, 1.5:1), 0.079 g (0.22 mmol) of the desired product in the form of a pale-yellow-coloured solid is obtained.
  • Example 3 Following the procedure described for the preparation of Example 3, starting from 1.00 g (3.64 mmol) of the compound obtained in Example 2 and 0.46 ml (0.57 g; 5.40 mmol) of chloroethyl isocyanate, 1.35 g (3.55 mmol) of the desired product in the form of a white-coloured solid are obtained.
  • Example 4 Following the procedure described for the preparation of Example 4, starting from 0.25 g (0.66 mmol) of the compound obtained in Example 33 and 0.17 g (0.71 mmol) of 72% 3-chloroperbenzoic acid, then purification by chromatography on silica gel (eluant: diethyl ether), 0.16 g (0.40 mmol) of the desired compound in the form of a white-coloured foam is obtained.
  • Example 3 Following the procedure described for the preparation of Example 3, starting from 0.50 g (1.82 mmol) of the compound obtained in Example 2 and 0.43 ml (0.56 g; 3.63 mmol) of 2,4-difluorophenyl isocyanate, then purification by chromatography on silica gel (eluant: pentane/diethyl ether, 4:1), 0.75 g (1.75 mmol) of the desired product in the form of a white-coloured solid is obtained.
  • silica gel eluant: pentane/diethyl ether, 4:1
  • Example 4 Following the procedure described for the preparation of Example 4, starting from 0.72 g (1.67 mmol) of the compound obtained in Example 35 and 0.45 g (1.88 mmol) of 72% 3-chloroperbenzoic acid, then purification by chromatography on silica gel (eluant: diethyl ether/petroleum ether, 1:1), 0.32 g (0.72 mmol) of the desired compound in the form of a white-coloured foam is obtained.
  • Example 3 Following the procedure described for the preparation of Example 3, starting from 0.25 g (0.86 mmol) of the compound obtained in Example 2 and 0.25 ml (0.34 g; 1.82 mmol) of 3-trifluoromethylphenyl isocyanate, then oxidation in accordance with the procedure described in Example 4, and finally purification by chromatography on silica gel (eluant: pentane/ethyl acetate, 4:1), 0.23 g (0.50 mmol) of the desired compound in the form of a white-coloured foam is obtained.
  • silica gel eluant: pentane/ethyl acetate, 4:1
  • Example 3 Following the procedure described for the preparation of Example 3, starting from 0.25 g (0.86 mmol) of the compound obtained in Example 2 and 0.26 ml (0.30 g; 1.79 mmol) of 1-naphthyl isocyanate, then oxidation in accordance with the procedure described in Example 4, and finally purification by chromatography on silica gel (eluant: methylene chloride/ethyl acetate, 4:1), 0.18 g (0.39 mmol) of the desired compound in the form of a white-coloured solid is obtained.
  • silica gel eluant: methylene chloride/ethyl acetate, 4:1
  • Step A 1,2:4,5-di-O-isopropylidene-3-O-allyl- ⁇ -D-fructopyranose
  • reaction mixture is poured into 100 ml of an aqueous ammonium chloride solution (10%) cooled to 0° C.
  • Customary treatment of the organic phase and then purification by chromatography on silica gel (eluant: pentane/diethyl ether, 8:1) yield 9.88 g (32.89 mmol) of the desired product in the form of a yellow-coloured oil.
  • Step B 1,2-O-isopropylidene-3-O-allyl- ⁇ -D-fructopyranose
  • step C Following the procedure described for the preparation of Example 1, step C, starting from 9.30 g (30.96 mmol) of the compound obtained in the preceding step, then purification by chromatography on silica gel (eluant: ethyl acetate/diethyl ether, 2:1), 6.04 g (23.20 mmol) of the desired product in the form of a white-coloured solid are obtained.
  • Example 2 Following the procedure described for the preparation of Example 2, starting from 1.00 g (3.84 mmol) of the compound obtained in Example 39 and 1.91 g of dibutyltin (7.67 mmol) at reflux for 48 hours in 30 ml of methanol and then using the intermediate formed in that reaction and subjecting it to the action of 1.20 ml (2.74 g; 19.27 mmol) of methyl iodide at reflux of dioxane (20 ml) for 60 hours, 0.92 g (3.35 mmol) of the desired compound in the form of a white-coloured foam is isolated after chromatography on silica gel (eluant: pentane/ethyl acetate, 2:1).
  • Example 4 Following the procedure described for the preparation of Example 4, starting from 1.18 g (4.30 mmol) of the compound obtained in Example 40 and 1.90 g (8.03 mmol) of 72% 3-chloroperbenzoic acid, then purification by chromatography on silica gel (eluant: diethyl ether), 0.53 g (1.82 mmol) of the desired diastereoisomeric mixture is obtained.
  • Example 42 5-O-Chloroacetylcarbamoyl-1,2-O-isopropylidene-3-[(2S)-(2:3-epoxypropyl)]-4-O-methyl- ⁇ -D-fructopyranose and 5-O-Chloroacetylcarbamoyl-1,2-O-isopropylidene-3-[(2R )-(2:3-epoxypropyl)]-4-O-methyl- ⁇ -D-fructopyranose ##STR42##
  • Example 3 Following the procedure described for the preparation of Example 3, starting from 0.50 g (1.72 mmol) of the mixture of diastereoisomers obtained in Example 41 and 0.25 ml (0.35 g; 2.93 mmol) of chloroacetyl isocyanate, then purification by chromatography (HPLC, Kromasil 100-5C18 column, eluant: acetonitrile/water, 3:7), 0.189 g (0.46 mmol) of the desired diastereoisomer A and 0.164 g (0.40 mmol) of diastereoisomer B, both in the form of a white-coloured foam, are obtained.
  • Step A 1,2:4,5-di-O-isopropylidene-3-(5-methylhex-1-enyl)- ⁇ -D-psicopyranose
  • Customary treatment of the organic phase yields 8.60 g of 1,2:4,5-di-O-isopropylidene-3-(5-methylhex-1-ynyl)- ⁇ -D-psicopyranose in the form of an oily residue, which is used for the following step without being purified.
  • Step B 1,2-O-isopropylidene-3-(5-methylhex-1-enyl)- ⁇ -D-psicopyranose
  • step C Following the procedure described for the preparation of Example 1 (step C), starting from 2.25 g (6.31 mmol) of the compound obtained in the preceding step, then evaporation of the 25 ml of acetic acid/water mixture, 4:1, 1.98 g (6.26 mmol) of the desired product in the form of a colourless oil are obtained.
  • Example 2 Following the procedure described for the preparation of Example 2, starting from 1.98 g (6.26 mmol) of the compound obtained in Example 43 and 3.15 g of dibutyltin (12.65 mmol) at reflux for 4 hours in 60 ml of methanol, and then using the intermediate formed in that reaction and subjecting it to the action of 6.50 ml (14.82 g; 104.41 mmol) of methyl iodide at reflux of dioxane (50 ml) for 37 hours, and after purification by chromatography on silica gel (eluant: pentane/diethyl ether, 3:1), 1.37 g (4.15 mmol) of the desired compound in the form of a white-coloured foam are obtained.
  • Example 45 1,2-O-Isopropylidene-3-[(2S,3S)-(3-isopentyloxiran-2-yl)]-4-O-methyl-.beta.-D-psicopyranose and 1,2-O-isopropylidene-3-[(2R,3R)-(3-isopentyloxiran-2-yl)]-4-O-methyl-.beta.-D-psicopyranose ##STR43##
  • Example 46 5-O-chloroacetylcarbamoyl-1,2-O-isopropylidene-3-[(2S,3S)-(3-isopentyloxiran-2-yl)]-4-O-methyl- ⁇ -D-psicopyranose and 5-O-chloroacetylcarbamoyl-1,2-O-isopropylidene-3-[(2R,3R )-(3-isopentyloxiran-2-yl)]-4-O-methyl- ⁇ -D-psicopyranose ##STR44##
  • Example 3 Following the procedure described for the preparation of Example 3, starting from 0.144 g (0.41 mmol) of diastereoisomer A obtained in Example 45 and 0.06 ml (0.08 g; 0.70 mmol) of chloroacetyl isocyanate, then purification by chromatography on silica gel (eluant: diethyl ether/pentane, 1:1), 0.175 g (0.37 mmol) of the desired compound in the form of a white-coloured solid is obtained.
  • Diastereoisomer B is obtained in accordance with the same procedure starting from diastereoisomer B obtained in Example 45.
  • Example 3 Following the procedure described for the preparation of Example 3, starting from 0.15 g (0.43 mmol) of diastereoisomer A obtained in Example 45 and 0.06 ml (0.08 g; 0.69 mmol) of ethoxycarbonyl isocyanate, then purification by chromatography on silica gel (eluant: pentane/diethyl ether, 1:1), 0.19 g (0.41 mmol) of the desired compound in the form of a white-coloured solid is obtained.
  • silica gel eluant: pentane/diethyl ether, 1:1
  • Example 3 Following the procedure described for the preparation of Example 3, starting from 0.15 g (0.43 mmol) of diastereoisomer A obtained in Example 45 and 0.06 ml (0.08 g; 0.66 mmol) of ethyl isocyanatoacetate, then purification by chromatography on silica gel (eluant: pentane/diethyl ether, 1:1), 0.17 g (0.36 mmol) of the desired compound in the form of a white-coloured solid is obtained.
  • silica gel eluant: pentane/diethyl ether, 1:1
  • Example 49 5-O-Chloroacetylcarbamoyl-1,2-O-isopropylidene-3-[(2S,3S)-(3-phenylpropyloxiran-2-yl)]-4-O-methyl- ⁇ -D-psicopyranose and 5-O-Chloroacetylcarbamoyl-1,2-O-isopropylidene-3-[(2R,3R)-(3-phenylpropyloxiran-2-yl) ]-4-O-methyl- ⁇ -D-psicopyranose ##STR45##
  • Step A 1,2:4,5-di-O-isopropylidene-3-methyloxalyl-3-(5-phenylpent-1-yne)- ⁇ -D-fructopyranose
  • Step B 1,2:4,5-di-O-isopropylidene-3-desoxy-3-(5-phenylpent-1-yne)- ⁇ -D-fructopyranose
  • Step C 5-O-Chloroacetylcarbamoyl-3-desoxy-1,2-O-isopropylidene-3-(3-phenylpropyloxiran-2-yl)-4-O-methyl- ⁇ -D-fructopyranose
  • That compound (0.55 g; 1.44 mmol) is dissolved in 9 ml of methylene chloride in the presence of 0.27 ml (3.17 mmol) of chloroacetyl isocyanate in accordance with the procedure described for the preparation of Example 3. After chromatography on silica gel (eluant: diethyl ether/pentane, 2:1), 0.74 g (1.19 mmol) of the desired product is obtained in the form of a white-coloured foam.
  • That compound (1.35 g; 4.88 mmol) is dissolved in 30 ml of methylene chloride in the presence of 1.25 ml (14.67 mmol) of chloroacetyl isocyanate, in accordance with the procedure described for the preparation of Example 3. After chromatography on silica gel (eluant: pentane/ethyl acetate, 2:1), 1.84 g (3.57 mmol) of the desired product are obtained in the form of a white-coloured foam.
  • Step A 1,2-O-isopropylidene-5-O-benzyl-4-O-methyl-3-(5-phenylpent-1-enyl)- ⁇ -D-psicopyranose
  • Step B 1,2-carbonate-5-O-benzyl-4-O-methyl-3-(5-phenylpent-1-enyl)- ⁇ -D-psicopyranose
  • reaction mixture is subsequently diluted with diethyl ether and then washed with a molar solution of hydrochloric acid.
  • organic phase is subsequently neutralised with sodium hydrogen carbonate and then dried over magnesium sulfate and evaporated.
  • An oily residue is obtained, which is chromatographed on silica gel (eluant: pentane/diethyl ether, 3:1). 0.80 g (1.77 mmol) of the desired compound in the form of a white foam is obtained.
  • Step C 1,2-carbonate-5-O-chloroacetylcarbamoyl-4-O-methyl-3-(5-phenylpentyl)-.beta.-D-psicopyranose
  • the cells are distributed on microplates and exposed to the cytotoxic compounds. The cells are then incubated for 2 days (L1210), 3 days (ECPA) and 4 days (A431). The number of viable cells is then quantified by means of a colorimetric assay, the Microculture Tetrazolium Assay (Carmichael J., DeGraff W. G., Gazdar A. F., Minna J. D. and Mitchell J. R., Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing, Cancer Res., 47, 936-942, (1987)).
  • the compounds of the present invention exhibited a very considerable cytotoxic effect on the three cell lines.
  • the IC 50 s concentration of cytotoxic agent that inhibit the proliferation of the treated cells by 50%
  • concentration of cytotoxic agent that inhibit the proliferation of the treated cells by 50% are from 3 to 10 times lower than those of fumagillin, depending upon the cell line.
  • Example B Inhibition of the neovascularisation of the chorio-allantoid membrane of chicken embryos

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

A compound selected from those of formula (I): <IMAGE> (I) in which: A either represents -OR6, and B represents -CH2-X, or, together with B and the carbon atom carrying them, forms an oxygen-containing heterocycle selected from oxirane, 2,2-dimethyl[1,3]dioxolane and [1,3]dioxolan-2-one, and R1, R2, R3, R4, R5, R6 and X are as defined in the description.

Description

The present invention relates to new glucidic compounds having a tetrahydropyran structure, to a process for the preparation thereof, and to pharmaceutical compositions containing them. The compounds of the present invention are highly valuable for therapeutic use on account of their angiogenesis-inhibiting ability.
Angiogenesis (or neovascularisation) is defined as the development and growth of new capillary blood vessels. The process of angiogenesis is essential in many physiological situations including the development of the embryo, the normal healing of injuries and the development of the endometrium after menstruation. Apart from those situations, angiogenesis in normal adults is very rare and the mitosis of the endothelial cells which produces the walls of the blood vessels is very slow, with cell renewal times which are measured in years.
Abnormal angiogenesis (that is to say, stimulation of the growth of new blood vessels owing to a pathological syndrome) is an established characteristic of many diseases, especially diabetic retinopathy, rheumatoid arthritis, haemangioma and the growth of solid tumours. Angiogenesis can also play an important part in other diseases, such as arterio-coronary disease.
In the field of oncology it has been shown that the growth of solid tumours is totally dependent upon the constant development of new blood vessels and that this is in correlation, for the metastases of certain cancers, with the increasing size of the primary tumour (J. Folkman, New Engl. Med., 285 (1974), 1182-1185).
Pharmaceutical treatment (that is to say, by means of an angiogenesis inhibitor) can, therefore, stop the growth of primary tumours, prevent or reduce the formation of metastases, and prevent the appearance of secondary growths. Such angiogenesis inhibitors are also useful in the treatment of non-neoplasic diseases mentioned above in which angiogenic activity occurs.
The needs of therapeutics demand the constant development of new angiogenesis-inhibiting compounds with the aim of obtaining active ingredients that are more active, more specific and, at the same time, less toxic.
The present invention relates to new compounds that have a tetrahydropyran structure and that are structurally and pharmacologically original as compared with the compounds described in the prior art.
More particularly, the present invention relates to compounds of the general formula (I): ##STR2## in which: A - either represents --OR6, and B represents --CH2 --X,
- or, together with B and the carbon atom carrying them, forms an oxygen-containing heterocycle selected from oxirane, 2,2-dimethyl[1,3]dioxolane and [1,3]dioxolan-2-one,
R1 - either represents the radical: ##STR3## in which Y and Z either each represent hydrogen or together form a double bond or together form, with the carbon atoms carrying them, an oxirane ring,
and R2 is selected from hydrogen, a hydroxy radical and the radical --OR9,
- or represents the radical: ##STR4## in which n is an integer from 1 to 4 inclusive and Y and Z either each represent hydrogen or together form a double bond or together form, with the carbon atoms carrying them, an oxirane ring,
and R2 represents hydrogen,
- or R1 represents hydrogen
and R2 represents the radical: ##STR5## as defined above, R3 is selected from hydrogen, a linear or branched, optionally substituted alkyl radical having from 1 to 6 carbon atoms, an optionally substituted benzyl radical, an optionally substituted benzoyl radical, an optionally substituted formyl radical, a linear or branched, optionally unsaturated and optionally substituted acyl radical having from 1 to 6 carbon atoms, an allyl radical, and an optionally mono- or di-substituted carbamoyl radical,
R4 - either is selected from a hydroxy radical, a linear or branched, optionally substituted alkoxy radical having from 1 to 6 carbon atoms, an optionally mono- or di-substituted carbamoyloxy radical, a piperazinylcarbonyloxy radical substituted in the 4-position by the radical R9, and an imidazol-1-ylcarbonyloxy radical, and R5 represents hydrogen,
- or, together with R5 and the carbon atom carrying them, forms a carbonyl group,
R6, R7 and R8 are selected, each independently of the others, from hydrogen, a linear or branched, optionally substituted alkyl radical having from 1 to 6 carbon atoms, and a phenylalkyl radical in which the phenyl group is optionally substituted and the alkyl group, which is linear or branched and is optionally substituted, has from 1 to 6 carbon atoms,
R9 is selected from hydrogen, a linear or branched, optionally substituted alkyl radical having from 1 to 6 carbon atoms, an optionally substituted formyl radical, a linear or branched, optionally unsaturated and optionally substituted acyl radical having from 1 to 6 carbon atoms, a linear or branched, optionally substituted alkoxycarbonyl radical having from 1 to 6 carbon atoms, an optionally substituted benzyl radical, and an optionally mono- or di-substituted carbamoyl radical,
X is selected from a hydroxy radical, a halogen atom, an optionally substituted phenylsulfonyloxy radical, and an optionally substituted linear or branched alkylsulfonyloxy radical having from 1 to 6 carbon atoms,
where appropriate their optical and geometrical isomers, in pure form or in the form of a mixture, and, where appropriate, their pharmaceutically acceptable addition salts with an acid,
wherein:
- the term "optionally mono- or di-substituted" associated with the above-defined carbamoyl and carbamoyloxy radicals indicates that one or both of the hydrogen atoms carried by the nitrogen atom may be substituted (independently of each other when both hydrogen atoms are substituted) by:
- a linear or branched, optionally substituted alkyl radical having from 1 to 6 carbon atoms,
- an optionally substituted formyl radical,
- a linear or branched, optionally unsaturated and optionally substituted acyl radical having from 1 to 6 carbon atoms,
- an optionally substituted benzoyl radical,
- an optionally substituted phenyl radical,
- an optionally substituted naphthyl radical, and
- an amino radical optionally substituted by one or two alkyl radicals having from 1 to 6 carbon atoms in a straight or branched chain, each alkyl radical being optionally substituted,
- the term "optionally substituted" associated with the alkyl, alkoxy, alkoxycarbonyl, formyl, acyl, benzyl, benzoyl, phenyl and naphthyl radicals indicates that those radicals may be substituted by one or more chemical entities selected from hydroxy, halogen, trihalomethyl, amino, alkylamino, dialkylamino, linear or branched alkoxy having from 1 to 6 carbon atoms, linear or branched alkoxycarbonyl having from 1 to 6 carbon atoms, and linear or branched acyl having from 1 to 6 carbon atoms,
- the term "optionally substituted" associated with the alkylsulfonyloxy and phenylsulfonyloxy radicals indicates that those radicals may be substituted by one or more linear or branched alkyl radicals having from 1 to 6 carbon atoms, and
- the term "unsaturated acyl radical" is to be understood as meaning more especially the acryloyl and methacryloyl radicals.
In the present invention, carbamoyl radical is to be understood as meaning the radical ##STR6## and carbamoyloxy radical is to be understood as meaning the radical ##STR7##
Of the acids that can be used for the formation of pharmaceutically acceptable salts there may be mentioned, by way of non-limiting example, hydrochloric acid, phosphoric acid, sulfuric acid, tartaric acid, citric acid, maleic acid, fumaric acid, etc..
The present invention relates also to a process for the preparation of a compound of formula (I), characterised in that 1,2:4,5-di-O-isopropylidene-β-D-fructopyranose of formula (II): ##STR8## prepared in accordance with the procedure described by E. J. Prisbe et al. (J. Org. Chem., 41, (1976), 1836-1846), is subjected
either: to an oxidising agent, such as pyridinium dichromate, so as to obtain the ketone of formula (lII): ##STR9## which is subjected to the action of a compound of formula (IVa) prepared from the corresponding vinyl halide: ##STR10## in which R7 and R8 are selected, each independently of the other, from hydrogen, a linear or branched, optionally substituted alkyl radical having from 1 to 6 carbon atoms, and a phenylalkyl radical in which the phenyl group is optionally substituted and the alkyl group, which is linear or branched and is optionally substituted, has from 1 to 6 carbon atoms,
in order to obtain the compound of formula (Va1): ##STR11## in which R7 and R8 are as defined above, which may optionally be subjected to the action of an alkyl halide, an acyl halide, a benzyl halide, an alkyl haloformate or an isocyanate in order to yield the compound of formula (Va2): ##STR12## in which R7 and R8 are as defined above and R'9 is selected from a linear or branched, optionally substituted alkyl radical containing from 1 to 6 carbon atoms, an optionally substituted formyl radical, an optionally substituted acyl radical containing from 1 to 6 carbon atoms, an optionally substituted benzyl radical, a linear or branched, optionally substituted alkoxycarbonyl radical containing from 1 to 6 carbon atoms, and an optionally mono- or di-substituted carbamoyl radical,
which compound of formula (Va1) may optionally be subjected to the action of methyloxalyl chloride, in the presence of n-butyllithium, so as to obtain the compound of formula (Va3): ##STR13## in which R7 and R8 are as defined above, which is then subjected to the action of tributyltin hydride in order to yield the compound of formula (Va4): ##STR14## in which R7 and R8 are as defined above, the totality of the compounds of formulae (Va1) and (Va2) forming the compound of formula (Va): ##STR15## in which R7 and R8 are as defined above and R9 is selected from hydrogen and the radical R'9 as defined above,
or: directly to the action of a compound of formula (IVb): ##STR16## in which R7 and R8 are as defined above and n is an integer from 1 to 4 inclusive,
in order to obtain the compound of formula (Vb): ##STR17## in which R7, R8 and n are as defined above,
the compounds of formulae (Va4), (Va) and (Vb) then being hydrolysed in an acidic medium, for example acetic acid, to yield the diols of formulae (VIa4), (VIa) and (VIb), respectively: ##STR18## in which R7, R8, R9 and n are as defined above, which compounds of formulae (VIa4), (VIa) and (VIb) may be regioselectively substituted in the presence of dibutyltin oxide so as to obtain the compounds of formulae (VIIa4), (VIIa) and (VIIb), respectively: ##STR19## in which R7, R8, R9 and n are as defined above and R'3 is selected from a linear or branched, optionally substituted alkyl radical having from 1 to 6 carbon atoms, an optionally substituted benzyl radical, an optionally substituted benzoyl radical, an optionally substituted formyl radical, a linear or branched, optionally unsaturated and optionally substituted acyl radical having from 1 to 6 carbon atoms, an allyl radical, and an optionally mono- or di-substituted carbamoyl radical,
it being possible for all of the compounds of formulae (VIa4) and (VIIa4), (VIa) and (VIIa) and (VIb) and (VIIb) optionally to be subjected to an epoxidation reagent, such as 3-chloroperbenzoic acid, in order to yield the compounds of formulae (VIIIa4), (VIIIa) and (VIIIb), respectively: ##STR20## in which R7, R8, R9 and n are as defined above and R3 is selected from hydrogen and the radical R'3 as defined above,
or alternatively to be subjected to catalytic hydrogenation in order to obtain the compounds of formulae (VIII'a4), (VIII'a) and (VIII'b), respectively: ##STR21## in which R3, R7, R8, R9 and n are as defined above, the totality of the compounds of formulae (VIa4), (VIa), (VIb), (VIIa4), (VIIa), (VIIb), (VIIIa4), (VIIIa), (VIIIb), (VIII'a4), (VIII'a) and (VIII'b) forming the compound of formula (VIII): ##STR22## in which: R1 - either represents the radical: ##STR23## in which Y and Z either each represent hydrogen or together form a double bond or together form, with the carbon atoms carrying them, an oxirane ring, and R7 and R8 are as defined above,
and R2 is selected from hydrogen, a hydroxy radical and the radical --OR9,
- or represents the radical: ##STR24## in which n is an integer from 1 to 4 inclusive and R7, R8, Y and Z are as defined above,
and R2 represents hydrogen,
- or R1 represents hydrogen
and R2 represents the radical: ##STR25## as defined above, and R3 is as defined above,
the compound of formula (VIII) then optionally being subjected:
- to the action of an alkylating agent under customary conditions, for example after formation of an anion by means of sodium hydride,
- to the action of an isocyanic compound in the presence or absence of an activator, such as 4-dimethylaminopyridine,
- or to the action of a carbonylating compound, carbonyldiimidazole, yielding the compound of formula (IXa): ##STR26## in which R1, R2 and R3 are as defined above, which compound, under the action of a piperazine substituted in the 4-position by the radical R9, itself yields the compound of formula (IXb): ##STR27## in which R1, R2, R3 and R9 are as defined above, the totality of the compounds of formulae (VIII), (IXa) and (IXb) forming the compound of formula (IX): ##STR28## in which R1, R2 and R3 are as defined above and R4 is selected from a hydroxy radical, a linear or branched, optionally substituted alkoxy radical having from 1 to 6 carbon atoms, an optionally mono- or di-substituted carbamoyloxy radical, a piperazinylcarbonyloxy radical substituted in the 4-position by the radical R9, and an imidazolylcarbonyloxy radical,
it also being possible for the compound of formula (VIII) to be subjected to the action of an oxidising agent under the conditions employed for the preparation of the compound of formula (III), so as to obtain the compound of formula (X): ##STR29## in which R1, R2 and R3 are as defined above, the totality of the compounds of formulae (IX) and (X) forming the compound of formula (XI): ##STR30## in which R1, R2 and R3 are as defined above and R4 and R5 are as defined for formula (I),
which compound (XI) may be:
- either: treated in accordance with customary methods of alcoholysis in order to form the compound of formula (XII): ##STR31## in which R1, R2, R3, R4 and R5 are as defined above and R'6 is selected from a linear or branched, optionally substituted alkyl radical having from 1 to 6 carbon atoms, and a phenylalkyl radical in which the phenyl group is optionally substituted and the alkyl group, which is linear or branched and is optionally substituted, has from 1 to 6 carbon atoms,
then subjected to customary substitution reactions so as to obtain the compound of formula (XIII): ##STR32## in which R1, R2, R3, R4, R5 and R'6 are as defined above and X' is selected from a halogen atom, an optionally substituted phenylsulfonyloxy radical, and an optionally substituted linear or branched alkylsulfonyloxy radical having from 1 to 6 carbon atoms,
- or: hydrolysed, under the action of an acidic resin, for example, to form the diol of formula (XIV): ##STR33## in which R1, R2, R3, R4 and R5 are as defined above,
then optionally subjected to customary substitution reactions so as to obtain the compound of formula (XV): ##STR34## in which R1, R2, R3, R4, R5 and X' are as defined above,
which compound of formula (XV), when X' represents an iodine atom, can be converted, under the action of silver oxide, into the epoxide of formula (XVI): ##STR35## in which R1, R2, R3, R4 and R5 are as defined above,
it also being possible for the compound of formula (XIV) to be subjected to the action of N,N-carbonyldiimidazole to yield the compound of formula (XVII): ##STR36## in which R1, R2, R3, R4 and R5 are as defined above,
the compounds of formulae (XI), (XII), (XIII), (XIV), (XV), (XVI) and (XVII) forming the compound of formula (I), which is optionally purified by a customary purification method and the optical and geometrical isomers of which are separated, if desired, by a customary separation method, and which are optionally converted into their pharmaceutically acceptable addition salts with an acid.
The compound of formula (Va1) in which R7 represents hydrogen can advantageously be obtained by reaction of an organolithium compound, prepared from the corresponding propargyl compound, of formula (IVa'): ##STR37## in which R8 is as defined above, then by catalytic hydrogenation of the resulting alkyne of formula (Va1 '): ##STR38## in which R8 is as defined above.
The compound of formula (VIII) can be protected regioselectively in the form of a silylated compound of formula (VIII'): ##STR39## in which R1 and R2 are as defined above and Ra, Rb and Rc each independently of the others represent a linear or branched alkyl radical containing from 1 to 6 carbon atoms, or a phenyl radical.
In general, the protection and deprotection of the hydroxy radicals carried by the pyranose compounds, the catalytic hydrogenation reactions and the epoxidation reactions by means of 3-chloroperbenzoic acid can be carried out at the time considered appropriate by the person skilled in the art, in the course of the synthesis of each compound.
The compounds of formula (I) have valuable pharmacological properties. In fact, the compounds are powerful angiogenesis inhibitors which have the advantage of being much less toxic as compared with the reference compounds. They therefore have an excellent therapeutic index. Accordingly, the compounds can be used in therapeutics as anti-tumour agents, in the inhibition of the formation and growth of metastases, as well as in the treatment of diabetic retinopathy, rheumatoid arthritis, haemangioma and arterio-coronary diseases, and more generally in disorders due to or associated with angiogenesis disorders.
The present invention relates also to pharmaceutical compositions comprising the compounds of formula (I), their stereoisomers, where appropriate, or, where appropriate, their pharmaceutically acceptable addition salts with an acid, on their own or in combination with one or more inert, non-toxic excipients or carriers.
Of the pharmaceutical compositions according to the invention there may be mentioned more especially those which are suitable for oral, parenteral, nasal, rectal, perlingual, ocular or respiratory administration, especially tablets, dragees, sublingual tablets, sachets, paquets, gelatin capsules, glossettes, lozenges, suppositories, creams, ointments, dermic gels, injectable or drinkable preparations, aerosols, ocular or nasal drops.
The dosage used varies according to the age and weight of the patient, the mode of administration and the nature of the therapeutic indication and of any associated treatments, and ranges from 0.01 to 1 g per day, in one or more administrations.
The Examples which follow illustrate the invention but do not limit it in any way. The starting materials are known or are prepared by known procedures.
The nomenclature used for naming the compounds of the invention is that recommended in "Modern Carbohydrate Chemistry" by Roger W. Binkley, Editions Marcel Dekker Inc., New York (1988).
The numbering and stereochemistry of β-D-psicopyranose which are used in the Examples which follow comply with the formula: ##STR40##
The numbering and stereochemistry of β-D-fructopyranose which are used in the Examples which follow comply with the formula: ##STR41##
EXAMPLE 1: 1,2-O-ISOPROPYLIDENE-3-ISOPROPENYL-β-D-PSICOPYRANOSE
Step A: 1,2:4,5-di-O-isopropylidene-β-n-erythro-2,3-hexodiulo-2,6-pyranose
2.44 g of 0.3 nm molecular sieve are added to 1.00 g (3.84 mmol) of 1,2:4,5-di-O-isopropylidene-β-D-fructopyranose, prepared in accordance with the procedure described by Prisbe E. J. et al. (J. Org. Chem., 41, (1976), 1836), dissolved in 20 ml of anhydrous methylene chloride. The reaction mixture is cooled to 10° C. with the aid of an ice-bath, and 1.38 g (6.48 mmol) of pyridinium dichromate followed by 0.3 ml (5.24 mmol) of glacial acetic acid are added. The reaction mixture is stirred at 10° C. for 5 hours and is then concentrated (to 5 ml ) in vacuo. 30 ml of diethyl ether are added and the whole is filtered. The filtrate is then evaporated and the resulting solid residue is chromatographed on silica gel (eluant: ethyl acetate/pentane, 3:2). 0.81 g (3.14 mmol) of the desired product in the form of a white-coloured solid is isolated.
Yield: 81%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.30 (3H, s); 1.31 (3H, s); 1.35 (3H, s); 1.48 (3H, s); 3.90 (1H, d); 4.05 (1H, d); 4.25 (1H, d); 4.40 (1H, d); 4.61 (1H, dd); 4.82 (1H, d).
Step B: 1,2:4,5-di-O-isopropylidene-3-isopropenyl-β-D-psicopyranose
5.69 ml of tert.-butyllithium (1.7M in pentane, i.e. 9.67 mmol) are added dropwise, under a nitrogen atmosphere, to a solution, cooled to -78° C., of 1.03 ml of 2-bromopropene (1.40 g; 11.59 mmol) in 8.5 ml of anhydrous diethyl ether. The whole is stirred at -78° C. for 5 minutes and then at 0° C. for one hour. The solution is then added dropwise to a solution, cooled to -78° C., of the product obtained in step A (1 g; 3.87 mmol) in 15 ml of anhydrous toluene. After 45 minutes' stirring at -78° C., the reaction mixture is poured into a 10% aqueous ammonium chloride solution (40 ml) cooled to 0° C. The whole is diluted with diethyl ether (100 ml) and the reaction mixture is extracted. Customary treatment of the organic phase yields an oily residue, which is chromatographed on silica gel (eluant: pentane/ethyl acetate, 8:1). 0.55 g (1.83 mmol) of the desired product is obtained in the form of a white foam.
Yield: 47%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): from 1.25 to 1.50 (12H, m); 1.85 (3H, s); 3.40 (1H, s, exchangeable with D2 O); 3.80 (1H, d); 4.00 (1H, d); 4.05 (2H, d); 4.34 (1H, dd); 4.45 (1H, d); 5.10 (1H, s); 5.25 (1H, s).
Step C: 1,2-O-isopropylidene-3-isopropenyl-β-D-psicopyranose
A solution of 4 g (13.32 mmol) of the compound obtained in step B in 100 ml of an acetic acid/water mixture, 4:1, is stirred at room temperature for 17 hours. The solvents are evaporated off under reduced pressure, the residue is taken up in 50 ml of toluene, and then evaporation is carried out again. That operation is repeated twice to yield, after 24 hours' drying under a high vacuum, 3.28 g (12.60 mmol) of the desired compound (purity >99% by gas chromatography) in the form of a white-coloured powder.
Yield: 96%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.30 (3H, s); 1.38 (3H, s); 1.85 (3H, s); 3.65 (1H, d); 3.75 (1H, d); 3.81 (1H, m); 3.82 (1H, m); 3.85 (1H, d); 4.10 (1H, d); 4.55 (1H, d, exchangeable with D2 O); 5.05 (1H, s); 5.08 (1H, s, exchangeable with D2 O); 5.16 (1H, s); 5.60 (1H, d, exchangeable with D2 O).
Example 2: 1,2-O-Isopropylidene-3-isopropenyl-4-O-methyl-β-D-psicopyranose
7.65 g (30.70 mmol) of dibutyltin oxide are added to a solution of 4 g (15.37 mmol) of the compound obtained in Example 1 in 120 ml of methanol. The heterogeneous reaction mixture is stirred and heated at reflux until a clear solution is obtained (approximately 24 hours). The mixture is cooled and then the solvent is evaporated off under reduced pressure. The solid residue is taken up in 70 ml of dioxane and is stirred under a nitrogen atmosphere. 6 ml (96.37 mmol) of methyl iodide are added and the whole is heated at reflux until the starting material has disappeared completely (approximately 60 hours). The dioxane is then evaporated off in vacuo and the resulting solid residue is chromatographed on silica gel (eluant: pentane/ethyl acetate, 2:1 then 1:1). 3.8 g (13.85 mmol) of the desired compound in the form of a white solid are obtained.
Yield: 90%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.25 (3H, s); 1.32 (3H, s); 1.80 (3H, s); 3.28 (3H, s); 3.50 (1H, d); 3.70 (2H, d); 3.82 (1H, d); 4.08 (1H, d); 4.18 (1H, s broad); 5.02 (1H, s); 5.15 (1H, s); 5.38 (1H, s, exchangeable with D2 O); 5.70 (1H, s broad, exchangeable with D2 O).
Example 3: 5-O-Chloroacetylcarbamoyl-1,2-O-isopropylidene-3-isopropenyl-4-O-methyl-.beta.-D-psicopyranose
2.39 ml (3.35 g; 28.05 mmol) of chloroacetyl isocyanate are added dropwise, under a nitrogen atmosphere, to a solution, cooled to 0° C., of 5.00 g (18.23 mmol) of the compound obtained in Example 2 in 90 ml of anhydrous methylene chloride. After 40 minutes' stirring at 0° C., the reaction mixture is poured into 50 ml of ice-water and the whole is stirred for one hour. After customary treatment of the organic phase and purification of the crude product by chromatography on silica gel (eluant: diethyl ether/petroleum ether, 4:1), 5.7 g (14.47 mmol) of the desired compound in the form of a white-coloured foam are obtained.
Yield: 79%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.30 (3H, s); 1.40 (3H, s); 1.83 (3H, s); 3.29 (3H, s); 3.75 to 3.90 (3H, m); 4.00 (1H, d); 4.10 (1H, s, exchangeable with D2 O); 4.12 (1H, d); 4.46 (2H, s); 5.09 (1H, s broad); 5.29 (1H, d); 5.41 (1H, s); 11.02 (1H, s, exchangeable with D2 O).
Elemental analysis: (empirical formula: C16 H24 ClNO8 M=393.82)
______________________________________                                    
          C    H          N      Cl                                       
______________________________________                                    
% found     48.78  5.80       3.82 9.03                                   
% calc.     48.80  6.14       3.56 9.00                                   
______________________________________
Example 4: 5-O-Chloroacetylcarbamoyl-1,2-O-isopropylidene-3-(2-methyloxiran-2-yl)-4-O-methyl-β-D-psicopyranose
5.00 g (21.15 mmol) of 72% 3-chloroperbenzoic acid are added to a solution of 5.70 g (14.47 mmol) of the compound obtained in Example 3 in 140 ml of methylene chloride. The reaction mixture is stirred at room temperature for 15 hours. The solid formed during the reaction is filtered and then the filtrate is evaporated under reduced pressure. The solid residue is purified by chromatography on silica gel (eluant: ethyl acetate/pentane, 2:1). The desired compound (4.20 g; 10.25 mmol) is obtained in the form of a white-coloured solid.
Yield: 70%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.40 (6H, s); 1.40 (3H, s); 2.45 (1H, d); 2.80 (1H, d); 3.33 (3H, s); 3.75 to 3.81 (3H, m); 3.85 (1H, s, exchangeable with D2 O); 4.00 (1H, d); 4.22 (1H, d); 4.46 (2H, s); 5.35 (1H, s broad); 10.90 (1H, s, exchangeable with D2 O).
Elemental analysis: (empirical formula: C16 H24 ClNO9 M=409.82)
______________________________________                                    
          C    H          N      Cl                                       
______________________________________                                    
% found     46.89  5.78       3.29 8.64                                   
% calc.     46.89  5.90       3.42 8.65                                   
______________________________________
Example 5: 1,2-O-Isopropylidene-3-isopropenyl-4-O-methyl-5-O-methylcarbamoyl-β-D-psicopyranose
0.90 ml (0.83 g; 14.56 mmol) of methyl isocyanate is added dropwise, under a nitrogen atmosphere, to a solution, cooled to 0° C. and containing 1.34 g (10.97 mmol) of 4-dimethylaminopyridine, of 2.00 g (7.29 mmol) of the compound obtained in Example 2 in 40 ml of anhydrous methylene chloride. After one hour's stirring at 0° C., the reaction mixture is poured into 20 ml of ice-water and the whole is stirred for one hour. After customary treatment of the organic phase and then purification of the crude product by chromatography on silica gel (eluant: diethyl ether), 2.3 g (6.94 mmol) of the desired compound in the form of a white-coloured foam are obtained.
Yield: 95%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.30 (3H, s); 1.40 (3H, s); 1.80 (3H, s); 2.60 (3H, d); 3.25 (3H, s); 3.70 to 3.75 (3H, t); 3.89 (1H, s, exchangeable with D2 O); 3.90 (1H, d); 4.12 (1H, d); 5.02 (1H, s); 5.20 (1H, s); 5.25 (1H, s); 7.30 (1H, q, exchangeable with D2 O).
Example 6: 1,2-O-Isopropylidene-3-(2-methyloxiran-2-yl)-4-O-methyl-5-O-methylcarbamoyl-β-D-psicopyranose
This compound is obtained in a manner identical to that described in Example 4, starting from 0.20 g (0.60 mmol) of the compound obtained in the preceding Example, 0.15 g (1.78 mmol) of solid sodium hydrogen carbonate and 0.22 g (0.93 mmol) of 72% 3-chloroperbenzoic acid.
Yield: 72%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.35 (9H, s); 2.40 (1H, d); 2.60 (3H, s); 2.75 (1H, d); 3.30 (3H, s); 3.65 (1H, s, exchangeable with D2 O); 3.70 to 3.80 (3H, m); 3.90 (1H, d); 4.20 (1H, d); 5.20 (1H, s broad); 7.20 (1H, q, exchangeable with D2 O).
Elemental analysis: (empirical formula: C15 H25 NO8 M=347.37)
______________________________________                                    
         C          H      N                                              
______________________________________                                    
% found    51.95        7.25   4.09                                       
% calc.    51.87        7.25   4.03                                       
______________________________________
Example 7: 5-O-Benzoylcarbamoyl-1,2-O-isopropylidene-3-isopropenyl-4-O-methyl-β-D-psicopyranose
Following the procedure described for the preparation of Example 5, starting from 1.20 g (4.37 mmol) of the compound obtained in Example 2 and 0.96 g (6.52 mmol) of benzoyl isocyanate, and after purification by chromatography on silica gel (eluant: diethyl ether/methylene chloride, 2:1), 1.30 g (3.08 mmol) of the desired product are obtained.
Yield: 70%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.30 (3H, s); 1.40 (3H, s); 1.85 (3H, s); 3.31 (3H, s); 3.72 (1H, d); 3.80 (1H, d); 3.89 (1H, d); 4.05 (1H, d); 4.15 (1H, d); 4.40 (1H, s, exchangeable with D2 O); 5.05 (1H, s broad); 5.25 (1H, s broad); 5.50 (1H, s broad); 7.52 (2H, t); 7.62 (1H, t); 7.90 (2H, d); 11.12 (1H, s, exchangeable with D2 O).
Example 8: 5-O-Benzoylcarbamoyl-1,2-O-isopropylidene-3-(2-methyloxiran-2-yl)-4-O-methyl-β-D-psicopyranose
Following the procedure described for the preparation of Example 4, starting from 0.25 g (0.59 mmol) of the compound obtained in Example 7 and 0.22 g (0.93 mmol) of 72% 3-chloroperbenzoic acid, then purification by chromatography on silica gel (eluant: diethyl ether/heptane, 5:1), 0.10 g (0.23 mmol) of the desired compound in the form of a white-coloured foam is collected.
Yield: 39%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.40 (9H, s); 2.41 (1H, d); 2.81 (1H, d); 3.35 (3H, s); 3.70 to 3.82 (3H, m); 4.00 (1H, d); 4.25 (1H, d); 4.30 (1H, s, exchangeable with D2 O); 5.40 (1H, s broad); 7.52 (2H, t); 7.61 (1H, t); 7.88 (2H, d); 10.96 (1H, s, exchangeable with D2 O).
Elemental analysis: (empirical formula: C21 H27 NO9 M=437.45)
______________________________________                                    
         C          H      N                                              
______________________________________                                    
% found    57.84        6.27   3.04                                       
% calc.    57.66        6.22   3.20                                       
______________________________________
Example 9: 3-Isopropenyl-4-O-methyl-5-O-methylcarbamoyl-β-D-psicopyranose
20 g of acidic resin (DOWEX 50X8-100) are added to a suspension of 1.10 g (3.24 mmol) of the compound obtained in Example 5 in 40 ml of water. The whole is heated at 60° C. for 80 minutes and is then stirred at room temperature for 1.5 hours. The reaction mixture is filtered and the filtrate is evaporated to give 0.92 g (3.15 mmol) of the desired triol in the form of a white foam.
Yield: 97%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.80 (3H, s); 2.60 (3H, d); 3.20 (3H, s); 3.35 to 3.60 (4H, m, of which 1H exchangeable with D2 O); 3.80 (1H, d); 4.00 (1H, m); 4.60 (1H, m, exchangeable with D2 O); 4.89 (1H, s broad); 5.15 (1H, s broad); 5.22 (1H, s broad); 5.50 (1H, s, exchangeable with D2 O); 7.25 (1H, q, exchangeable with D2 O).
Example 10: 1-(para-Toluenesulfonyl)-3-isopropenyl-4-O-methyl-5-O-methylcarbamoyl-.beta.-D-psicopyranose
8.94 g (46.89 mmol) of tosyl chloride are added, at room temperature and under a nitrogen atmosphere, to a solution of 3.90 g (13.39 mmol) of the triol obtained in Example 9 in 40 ml of anhydrous pyridine. After 2 hours' stirring at room temperature, the reaction mixture is poured into 30 ml of an aqueous ammonium chloride solution (10%) cooled to 0° C. The reaction mixture is then diluted in 200 ml of ethyl acetate and then the two phases are separated. After customary treatment of the organic phase and purification of the crude product by chromatography on silica gel (eluant: diethyl ether), 4.98 g (11.18 mmol) of the desired product in the form of a white foam are obtained.
Yield: 83%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.70 (3H, s); 2.40 (3H, s); 2.70 (3H, d); 3.25 (3H, s); 3.60 (1H, d); 3.75 (1H, s, exchangeable with D2 O); 3.80 (1H, d); 3.90 to 4.00 (3H, m); 4.85 (1H, s broad); 5.05 (1H, s broad); 5.20 (1H, s broad); 6.60 (1H, s, exchangeable with D2 O); 7.22 (1H, q, exchangeable with D2 O); 7.48 (2H, d); 7.75 (2H, d).
Example 11: 1-(para-Toluenesulfonyl)-3-(2-methyloxiran-2-yl)-4-O-methyl-5-O-methylcarbamoyl-β-D-psicopyranose
Following the procedure described for the preparation of Example 4, starting from 0.25 g (0.56 mmol) of the compound obtained in the preceding Example and 0.21 g (0.89 mmol) of 72% 3-chloroperbenzoic acid, then purification by chromatography on silica gel (eluant: pentane/ethyl acetate, 1:1), 0.16 g of the desired product in the form of a white-coloured foam is obtained.
Yield: 61%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.80 (3H, s); 2.20 (1H, d); 2.40 (3H, s); 2.50 (1H, m); 2.55 (3H, d); 3.25 (3H, s); 3.44 (1H, s, exchangeable with D2 O); 3.60 (1H, d); 3.80 to 3.85 (2H, m); 4.00 (1H, d); 4.10 (1H, d); 5.11 (1H, s broad); 6.72 (1H, s, exchangeable with D2 O); 7.05 (1H, q, exchangeable with D2 O); 7.49 (2H, d); 7.80 (2H, d).
Elemental analysis: (empirical formula: C19 H27 NO10 S M=461.48)
______________________________________                                    
          C    H          N      S                                        
______________________________________                                    
% found     49.83  6.34       3.15 6.64                                   
% calc.     49.45  5.90       3.04 6.95                                   
______________________________________
Example 12: 1-Bromo-1-desoxy-3-isopropenyl-4-O-methyl-5-O-methylcarbamoyl-β-D-psicopyranose
0.29 g (3.34 mmol) of lithium bromide is added at room temperature, in a single portion, to a solution of 0.31 g (0.69 mmol) of the compound obtained in Example 10 in 15 ml of acetone. The reaction mixture is placed under stirring and then heated at 75° C. for 1.5 hours. A further 0.26 g (2.99 mmol) of lithium bromide is then added and the whole is again heated at 75° C. for one hour. The acetone is evaporated off under reduced pressure and the residue is taken up in 20 ml of ethyl acetate. Customary treatment of the organic phase yields 0.23 g (0.65 mmol) of the desired product in the form of a white-coloured foam.
Yield: 94%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.80 (3H, s); 2.60 (3H, d); 3.22 (3H, s); 3.52 (1H, d); 3.70 (1H, d); 3.78 (1H, d); 3.82 (1H, s, exchangeable with D2 O); 3.89 (1H, d); 4.05 (1H, d); 4.95 (1H, s broad); 5.20 (1H, s broad); 5.23 (1H, s broad); 6.20 (1H, s, exchangeable with D2 O); 7.30 (1H, q, exchangeable with D2 O).
Example 13: 1-Bromo-1-desoxy-3-(2-methyloxiran-2-yl)-4-O-methyl-5-O-methylcarbamoyl-.beta.-D-psicopyranose
Following the procedure described for the preparation of Example 4, starting from 0.23 g (0.65 mmol) of the compound obtained in the preceding Example and 0.23 g (0.97 mmol) of 72% 3-chloroperbenzoic acid, then purification by chromatography on silica gel (eluant: diethyl ether), 0.16 g (0.43 mmol) of the desired compound in the form of a white-coloured solid is obtained.
Yield: 66%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.35 (3H, s); 2.32 (1H, d); 2.58 (3H, d); 2.72 (1H, d); 3.28 (3H, s); 3.45 (1H, s, exchangeable with D2 O); 3.62 (1H, d); 3.69 (2H, s); 3.90 (1H, d); 3.99 (1H, d); 5.12 (1H, s broad); 6.32 (1H, s, exchangeable with D2 O); 7.10 (1H, q, exchangeable with D2 O).
Elemental analysis: (empirical formula: C12 H20 BrNO7 M=370.20)
______________________________________                                    
          C    H          N      Br                                       
______________________________________                                    
% found     38.72  5.18       3.83 21.64                                  
% calc.     38.93  5.45       3.78 21.58                                  
______________________________________
Example 14: 1,2-O-Isopropylidene-3-isopropenyl-4,5-di-O-methyl-β-D-psicopyranose
3.28 g (12.60 mmol) of the compound obtained in Example 1 in solution in 35 ml of anhydrous N,N-dimethylformamide are added dropwise, at room temperature, to a suspension of sodium hydride (60% in oil; 1.10 g; 27.50 mmol) in 50 ml of anhydrous N,N-dimethylformamide. The reaction mixture is stirred at room temperature for 30 minutes and is then cooled to 0° C. before the dropwise addition of 2.35 ml (5.36 g; 37.75 mmol) of methyl iodide. After 50 minutes' stirring at 0° C., the reaction mixture is poured into 100 ml of an aqueous ammonium chloride solution (10%) cooled to 0° C. Customary treatment of the organic phase yields, after purification by chromatography on silica gel (eluant: pentane/ethyl acetate, 8:1 then 5:1), 2.93 g (10.16 mmol) of the desired product in the form of a yellow-coloured oil.
Yield: 80%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.29 (3H, s); 1.35 (3H, s); 1.80 (3H, s); 3.30 (3H, s); 3.40 (3H, s); 3.65 (1H, d); 3.72 (2H, m); 3.95 (1H, s); 3.97 (1H, d); 4.05 (1H, d); 4.49 (1H, s, exchangeable with D2 O); 5.02 (1H, s broad); 5.15 (1H, s broad).
Example 15: 1,2-O-Isopropylidene-3-(2-methyloxiran-2-yl)-4,5-di-O-methyl-β-D-psicopyranose
Following the procedure described for the preparation of Example 4, starting from 0.44 g (1.52 mmol) of the compound obtained in Example 14 and 0.40 g (1.69 mmol) of 72% 3-chloroperbenzoic acid, then purification by chromatography on silica gel (eluant: pentane/ethyl acetate, 1.5:1), 0.27 g (0.89 mmol) of the desired compound in the form of a white-coloured solid is obtained.
Yield: 58%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.40 (3H, s); 1.44 (6H, s); 2.22 (1H, d); 2.95 (1H, d); 3.35 (3H, s); 3.40 (3H, s); 3.60 (1H, d); 3.66 to 3.72 (2H, m); 3.92 (1H, d); 3.96 (1H, d); 4.40 (1H, s, exchangeable with D2 O); 4.56 (1H, d).
Elemental analysis: (empirical formula: C14 H24 O7 M=304.34)
______________________________________                                    
               C    H                                                     
______________________________________                                    
% found          55.92  7.99                                              
% calc.          55.25  7.95                                              
______________________________________
Example 16: 1,2-O-Isopropylidene-3-(2-methyloxiran-2-yl)-4-O-methyl-β-D-psicopyranose
Following the procedure described for the preparation of Example 4, starting from 0.25 g (0.91 mmol) of the compound obtained in Example 2 and 0.34 g (1.44 mmol) of 72% 3-chloroperbenzoic acid, then purification by chromatography on silica gel (eluant: pentane/ethyl acetate, 2:1), 0.17 g (0.58 mmol) of the desired compound in the form of a white-coloured foam is obtained.
Yield: 63%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.35 (9H, s); 2.42 (1H, d); 2.75 (1H, d); 3.20 (3H, s); 3.50 (1H, s); 3.65 to 3.85 (3H, m); 4.10 (1H, s broad); 4.20 (1H, d); 4.95 (1H, s, exchangeable with D2 O); 5.15 (1H, d, exchangeable with D2 O).
Elemental analysis: (empirical formula: C13 H22 O7 M=290.31)
______________________________________                                    
               C    H                                                     
______________________________________                                    
% found          54.14  7.73                                              
% calc.          53.78  7.64                                              
______________________________________
Example 17: 1,2-O-Isopropylidene-2,5-hexodiulo-3-(2-methyloxiran-2-yl)-4-O-methyl-.beta.-D-erythro-2,6-pyranose
0.70 g (1.86 mmol) of pyridinium dichromate is added to a solution of the compound obtained in Example 16 (0.22 g; 0.76 mmol) in 5 ml of anhydrous methylene chloride containing 0.50 g of activated molecular sieve (0.4 nm). The whole is stirred at room temperature for 22 hours and then the reaction mixture is immediately chromatographed on silica gel (eluant: ethyl acetate/pentane, 2:1) to give 0.13 g (0.45 mmol) of the desired ketone in the form of a white-coloured solid.
Yield: 59%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.45 (9H, s); 2.50 (1H, m); 2.80 (1H, d); 3.50 (3H, s); 3.85 (1H, d); 3.90 (1H, d); 4.20 (1H, d); 4.30 (1H, d); 4.50 (1H, s); 4.70 (1H, s, exchangeable with D2 O).
Elemental analysis: (empirical formula: C13 H20 O7 M=288.30)
______________________________________                                    
               C    H                                                     
______________________________________                                    
% found          53.77  7.05                                              
% calc.          54.16  6.99                                              
______________________________________
Example 18: 5-O-(1-Imidazolylcarbonyl)-1,2-O-isopropylidene-3-(2-methyloxiran-2-yl)-4-O-methyl-β-D-psicopyranose
3.35 g (20.66 mmol) of carbonyldiimidazole are added in a single portion, under a nitrogen atmosphere and at room temperature, to a solution of the compound obtained in Example 16 (2.00 g; 6.89 mmol) in 40 ml of anhydrous methylene chloride. The reaction mixture is stirred at room temperature for 5 hours. The solvent is then evaporated off under reduced pressure and the resulting solid residue is chromatographed on silica gel (eluant: ethyl acetate/pentane, 2:1). In this manner, 2.33 g (6.06 mmol) of the desired compound in the form of a white foam are obtained.
Yield: 88%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.40 (9H, 2s); 2.80 (1H, m); 2.84 (1H, d); 3.40 (3H, s); 3.82 (1H, d); 3.90 (1H, d); 4.02 (2H, m); 4.25 (1H, d); 4.45 (1H, s, exchangeable with D2 O); 5.50 (1H, s broad); 7.06 (1H, s); 7.65 (1H, s); 8.30 (1H, s).
Elemental analysis: (empirical formula: C17 H24 N2 O8 M=384.39)
______________________________________                                    
         C          H      N                                              
______________________________________                                    
% found    53.04        6.30   7.05                                       
% calc.    53.12        6.29   7.29                                       
______________________________________
Example 19: 5-O-{1-[4-((2,3,4-Trimethoxybenzyl)piperazinyl)]carbonyl}-1,2-O-isopropylidene-3-(2-methyloxiran-2-yl)-4-O-methyl-β-D-psicopyranose
1.50 g (5.63 mmol) of 4-[(2,3,4-trimethoxybenzyl)piperazine] (TRIMETAZIDINE®) are added, at room temperature and under a nitrogen atmosphere, to a solution of the compound obtained in Example 18 (1.00 g; 2.60 mmol) in 6 ml of anhydrous methylene chloride. The reaction mixture is stirred at room temperature for 17 hours and then the solvent is evaporated off under reduced pressure. The yellow-coloured oily residue that is obtained is purified on a column of silica gel (eluant: ethyl acetate). 1.15 g (1.97 mmol) of the desired product in the form of a white foam are isolated.
Yield: 75%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.40 (9H, 2s); 2.25 (4H, s broad); 2.43 (1H, m); 2.80 (1H, d); 3.35 (6H, m); 3.60 (1H, s, exchangeable with D2 O); 3.70 (1H, m); 3.71 (3H, s); 3.75 (2H, m); 3.78 (9H, s); 3.90 (1H, d); 4.19 (1H, d); 5.15 (1H, d); 6.77 (1H, d); 6.96 (1H, d).
Elemental analysis: (empirical formula: C28 H42 N2 O11 M=582.65)
______________________________________                                    
         C          H      N                                              
______________________________________                                    
% found    57.69        7.16   4.72                                       
% calc.    57.72        7.27   4.81                                       
______________________________________
Example 20: 5-O-[1-(4-Chloroacetylpiperazinyl)carbonyl]-1,2-O-isopropylidene-3-(2-methyloxiran-2-yl)-4-O-methyl-β-D-psicopyranose
1.5 g (2.74 mmol) of ceric ammonium nitrate are added at 0° C. to a solution of the compound obtained in Example 19 (0.50 g ;0.86 mmol) in 12 ml of an acetonitrile/water mixture (2:1). The reaction mixture is stirred for 2.5 hours, the temperature being allowed gradually to approach room temperature. After evaporation of the solvents, the residue is chromatographed on silica gel (eluant: methylene chloride/methanol/ammonia, 90: 10:0.5). 0.16 g (0.40 mmol) of debenzylated compound is obtained. To a solution of 0.15 g (0.37 mmol) of that compound in 5 ml of anhydrous methylene chloride containing 0.15 ml (0.11 g; 1.08 mmol) of anhydrous triethylamine there is added dropwise at 0° C., under a nitrogen atmosphere, 0.045 ml (0.064 g; 0.56 mmol) of chloroacetic acid chloride. The reaction mixture is stirred at 0° C. for 1 hour 45 minutes and then the whole is poured into an aqueous ammonium chloride solution (10%) cooled to 0° C. After customary treatment of the organic phase and then purification by chromatography on silica gel (eluant: ethyl acetate), 0.086 g (0.18 mmol) of the desired product in the form of a beige foam is obtained.
Overall yield: 22%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.40 (9H, 3s); 2.43 (1H, d); 2.80 (1H, d); 3.30 (3H, s); 3.40 (8H, s broad); 3.80 (4H, m, of which 1 exchangeable with D2 O); 3.92 (1H, d); 4.20 (1H, d); 4.40 (2H, s); 5.18 (1H, s broad).
Elemental analysis: (empirical formula: C20 H31 ClN2 O9 M=478.93)
______________________________________                                    
          C    H          N      Cl                                       
______________________________________                                    
% found     49.80  6.41       5.71 7.73                                   
% calc.     50.16  6.52       5.85 7.40                                   
______________________________________
Example 21: 5-O-[1-(4-Formylpiperazinyl)carbonyl]-1,2-O-isopropylidene-3-(2-methyloxiran-2-yl)-4-O-methyl-β-D-psicopyranose
This synthesis is carried out under the same operating conditions as those described for the preparation of Example 19, starting from 0.50 g of the compound obtained in Example 18 (1.30 mmol) and 0.40 ml (0.44 g; 3.88 mmol) of N-formylpiperazine in 5 ml of anhydrous methylene chloride. 0.36 g (0.84 mmol) of the desired product in the form of a white-coloured powder is obtained.
Yield: 64%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.40 (9H, s); 2.48 (1H, d); 2.80 (1H, d); 3.30 (3H, s); 3.35 (8H, m); 3.70 to 3.85 (4H, m, of which 1H exchangeable with D2 O); 3.92 (1H, d); 4.21 (1H, d); 5.20 (1H, s broad); 8.06 (1H, s).
Elemental analysis: (empirical formula: C19 H30 N2 O9 M=430.46)
______________________________________                                    
         C          H      N                                              
______________________________________                                    
% found    52.95        6.99   6.51                                       
% calc.    53.02        7.02   6.51                                       
______________________________________
Example 22: 4,5-di-O-Chloroacetylcarbamoyl-1,2-O-isopropylidene-3-isopropenyl-β-D-psicopyranose
Following the procedure described for the preparation of Example 3, starting from 0.50 g (1.82 mmol) of the compound obtained in Example 1 and 0.50 ml (0.70 g; 5.87 mmol) of chloroacetyl isocyanate, then purification by chromatography on silica gel (eluant: ethyl acetate/pentane, 1:1), 0.90 g (1.80 mmol) of the desired product in the form of a white-coloured solid is obtained.
Yield: 98%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.30 (3H, s); 1.40 (3H, s); 1.75 (3H, s); 3.85 (2H, m); 4.15 (2H, m); 4.25 (1H, s, exchangeable with D2 O); 4.30 (2H, s); 4.50 (2H, s); 5.15 (1H, s); 5.25 (2H, s); 5.30 (1H, s); 11.10 (1H, s, exchangeable with D2 O); 11.18 (1H, s, exchangeable with D2 O).
Elemental analysis: (empirical formula: C18 H24 Cl2 N2 O10 M=499.30)
______________________________________                                    
          C    H          N      Cl                                       
______________________________________                                    
% found     43.70  4.84       5.56 14.24                                  
% calc.     43.30  4.94       5.61 14.20                                  
______________________________________
Example 23: 4,5-di-O-Chloroacetylcarbamoyl-1,2-O-isopropylidene-3-(2-methyloxiran-2- yl)-β-D-psicopyranose
Following the procedure described for the preparation of Example 4, starting from 0.30 g (0.60 mmol) of the product described in Example 22 and 0.17 g (0.72 mmol) of 72% 3-chloroperbenzoic acid, then purification by chromatography on silica gel (eluant: diethyl ether), 0.19 g (0.38 mmol) of the desired product in the form of a white-coloured foam is obtained.
Yield: 63%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.35 (3H, s); 1.41 (6H, 2s); 2.50 (1H+DMSO, s broad); 2.99 (1H, d); 3.72 (1H, d); 3.85 (1H, s); 4.00 (1H, s, exchangeable with D2 O); 4.12 (1H, d); 4.25 (1H, d); 4.40 (2H, s); 4.52 (2H, s); 5.20 (1H, s broad); 5.30 (1H, s broad); 11.06 (1H, s, exchangeable with D2 O); 11.20 (1H, s, exchangeable with D2 O).
Elemental analysis: (empirical formula: C18 H24 Cl2 N2 O11 M=515.30)
______________________________________                                    
          C    H          N      Cl                                       
______________________________________                                    
% found     41.78  4.83       5.26 14.04                                  
% calc.     41.96  4.69       5.44 13.76                                  
______________________________________
Example 24: 5-O-Phenylcarbamoyl-1,2-O-isopropylidene-3-(2-methyloxiran-2-yl)-4-O-methyl-β-D-psicopyranose
The title compound is obtained starting from the compound described in Example 2, in accordance with the procedure described in Example 3, by replacing chloroacetyl isocyanate with phenyl isocyanate and then carrying out the oxidation described in Example 4.
Elemental analysis: (empirical formula: C20 H27 NO8 M=409.44)
______________________________________                                    
         C          H      N                                              
______________________________________                                    
% found    58.95        6.39   3.48                                       
% calc.    58.67        6.65   3.42                                       
______________________________________
Example 25: 1,2-O-Isopropylidene-3-isopropenyl-3,4-di-O-methyl-β-D-psicopyranose
Step A: 5-O-tert.butyldimethylsilyl-1,2-O-isopropylidene-3-isopropenyl-3,4-di-O-methyl-β-D-psicopyranose
1.24 g (18.21 mmol) of imidazole and 1.92 g (12.73 mmol) of tert.-butyldimethylsilyl chloride are added in succession to a solution, cooled to 0° C., of 2.00 g (7.29 mmol) of the compound obtained in Example 2 in 10 ml of anhydrous N,N-dimethylformamide. The whole is stirred for 72 hours, the temperature being allowed to approach room temperature. The intermediate product is isolated and purified by chromatography on silica gel (eluant: petroleum ether/ethyl acetate, 4:1) to give 2.72 g (7.00 mmol) of the desired compound in the form of a white-coloured solid. A solution of that product (1.18 g; 3.04 mmol) in 5 ml of anhydrous tetrahydrofuran is added to a suspension of sodium hydride (0.22 g; 5.50 mmol) in 6 ml of anhydrous tetrahydrofuran. The whole is stirred under a nitrogen atmosphere at reflux of the solvent for 55 minutes, and 1.15 ml (2.62 g; 18.47 mmol) of methyl iodide are added. The reaction mixture is heated at reflux of the tetrahydrofuran for a further 1.5 hours and then the whole is poured into an aqueous ammonium chloride solution (10%) cooled to 0° C. After customary treatment of the organic phase and purification by chromatography on silica gel (eluant: methylene chloride), 0.86 g (2.14 mmol) of the desired compound in the form of a white-coloured loam is obtained.
Yield: 67%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 0.10 (6H, s); 0.30 (9H, s); 1.20 (3H, s); 1.30 (3H, s); 1.70 (3H, s); 3.30 (3H, s); 3.35 (3H, s); 3.50 to 3.60 (2H, in); 3.65 (1H, d); 3.70 (1H, d); 4.10 (1H, d); 4.20 (1H, s broad); 5.00 (1H, s broad); 5.20 (1H, s).
Step B: 1,2-O-isopropylidene-3-isopropenyl-3,4-di-O-methyl-β-D-psicopyranose
6.5 ml of a solution (1M in tetrahydrofuran) of tetrabutylanunonium fluoride (6.50 mmol) are added rapidly to a solution, cooled to 0° C., of the compound obtained in the preceding step (0.85 g; 2.11 mmol) in 6 ml of anhydrous tetrahydrofuran. The whole is stirred for 5 hours, the temperature being allowed to approach room temperature. After customary treatment of the organic phase and purification by chromatography on silica gel (eluant: pentane/diethyl ether, 1:1), 0.60 g (2.09 mmol) of the desired compound in the form of a colourless oil is obtained.
Yield: 99%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.30 (3H, s); 1.40 (3H, s); 1.90 (3H, s); 3.30 (3H, s); 3.40 (3H, s); 3.65 to 3.75 (3H, m); 3.80 (1H, dxd); 4.20 (1H, m); 4.30 (2H, m, of which 1 exchangeable with D2 O); 5.00 (1H, s broad); 5.30 (1H, s broad).
Example 26: 5-O-Chloroacetylcarbamoyl-1,2-O-isopropylidene-3-isopropenyl-3,4-di-O-methyl-β-D-psicopyranose
Following the procedure described for the preparation of Example 3, starting from 0.10 g (0.35 mmol) of the compound obtained in Example 25 and 0.05 ml (0.07 g; 0.59 mmol) of chloroacetyl isocyanate, purification by chromatography on silica gel (eluant: diethyl ether) yields 0.14 g (0.34 mmol) of the desired product in the form of a white-coloured foam.
Yield: 97%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.30 (3H, s); 1.40 (3H, s); 1.90 (3H, s); 3.30 (3H, s); 3.40 (3H, s); 3.75 (1H, d); 3.80 (1H, d); 3.95 (1H, d); 4.00 (1H, d); 4.25 (1H, d); 4.45 (2H, s); 5.05 (1H, s); 5.35 (1H, s); 5.40 (1H, s broad); 11.10 (1H, s, exchangeable with D2 O).
Example 27: 1,2-O-Isopropylidene-3,4-di-O-methyl-3-(2-methyloxiran-2-yl)-β-D-psicopyranose
Following the procedure described for the preparation of Example 4, starting frown 0.27 g (0.94 mmol) of the product described in Example 25 and 0.81 g (3.38 mmol) of 72% 3-chloroperbenzoic acid, then purification by chromatography on silica gel (eluant: diethyl ether), 0.25 g (0.82 mmol) of the desired product in the form of a white-coloured solid is obtained.
Yield: 87%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.40 (9H, 2s); 2.45 (1H, d); 2.90 (1H, d); 3.35 (6H, 2s); 3.60 (1H, d); 3.65 (1H, dd); 3.85 (1H, d); 3.90 (1H, dd); 4.00 (1H, m); 4.40 (1H, d, exchangeable with D2 O); 4.55 (1H, d).
Example 28: 5-O-Chloroacetylcarbamoyl-1,2-O-isopropylidene-3,4-di-O-methyl-3-(2-methyloxiran-2-yl)-β-D-psicopyranose
Following the procedure described for the preparation of Example 3, starting from 0.23 g (0.75 mmol) of the product obtained in Example 27 and 0.08 ml (0.11 g; 0.94 mmol) of chloroacetyl isocyanate, then purification by chromatography on silica gel (eluant: methylene chloride/ethyl acetate, 4:1), 0.25 g (0.59 mmol) of the desired product in the form of a white-coloured foam is obtained.
Yield: 78%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.35 (9H, 2s); 2.50 (1H, d); 2.80 (1H, d); 3.35 (6H, 2s); 3.60 (1H, d); 3.72 (2H, 2d); 4.00 (1H, d); 4.40 (2H, s); 4.55 (1H, d); 5.35 (1H, s broad); 11.02 (1H, s, exchangeable with D2 O).
Elemental analysis: (empirical formula: C17 H26 ClNO9 M=423.85)
______________________________________                                    
          C    H          N      Cl                                       
______________________________________                                    
% found     49.84  6.41       3.23 8.26                                   
% calc.     48.17  6.18       3.30 8.37                                   
______________________________________
Example 29: 3-Isopropenyl-4,5-di-O-methyl-β-D-psicopyranose
Following the procedure described for the preparation of Example 9, starting from 1.00 g (3.47 mmol) of the compound obtained in Example 14 and 25 g of acidic resin (DOWEX 50X8-100) heated in 50 ml of water, then purification by chromatography on silica gel (eluant: diethyl ether then ethyl acetate), 0.59 g (2.38 mmol) of the desired product in the form of a white-coloured solid is obtained.
Yield: 68%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.75 (3H, s); 3.30 (3H, s); 3.35 (1H, m); 3.52 (3H, s); 3.55 (1H, dd); 3.70 to 3.90 (4H, m); 4.30 (1H, s, exchangeable with D2 O); 4.50 (1H, t, exchangeable with D2 O); 4.86 (1H, s); 5.10 (1H, s); 5.40 (1H, s, exchangeable with D2 O).
Example 30: 1-para-Toluenesulfonyl-3-isopropenyl-4,5-di-O-methyl-β-D-psicopyranos
Following the procedure described for the preparation of Example 10, starting from 0.80 g (3.22 mmol) of the compound obtained in Example 29 and 1.53 g of tosyl chloride in 15 ml of anhydrous pyridine, then purification by chromatography on silica gel (eluant: diethyl ether/pentane, 2:1), 0.92 g (2.28 mmol) of the desired product in the form of a white-coloured foam is obtained.
Yield: 70%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.62 (3H, s); 2.40 (3H, s); 3.22 (3H, s); 3.34 (3H, s); 3.68 (1H, d); 3.75-3.85 (3H, m); 3.90 (1H, d); 3.98 (1H, d); 4.40 (1H, s, exchangeable with D2 O); 4.81 (1H, s broad); 4.95 (1H, d); 6.46 (1H, s, exchangeable with D2 O); 7.45 (2H, d); 7.71 (2H, d).
Example 31: 1-Desoxy-1-iodo-3-isopropenyl-4,5-di-O-methyl-β-D-psicopyranose
Following the procedure described for the preparation of Example 12, starting from 0.10 g (0.25 mmol) of the compound obtained in Example 30 and 0.18 g (1.20 mmol) of sodium iodide in 3 ml of acetone at room temperature, then purification by chromatography on silica gel (eluant: diethyl ether/pentane, 1.5:1), 0.079 g (0.22 mmol) of the desired product in the form of a pale-yellow-coloured solid is obtained.
Yield: 88%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.76 (3H, s); 3.25 (4H, s+d); 3.40 (3H, s); 3.64 (1H, d); 3.75 to 3.95 (4H, m); 4.50 (1H, s, exchangeable with D2 O); 4.95 (1H, s broad); 5.15 (1H, s broad); 5.98 (1H, s, exchangeable with D2 O).
Example 32: (3R,6R,7R,8R)-8-Isopropenyl-6,7-dimethoxy-1,4-dioxaspiro[2,5]octan-8-ol
2.20 g (9.49 mmol) of silver(I) oxide are added in portions, over a period of 48 hours, to a solution of the compound obtained in Example 31 (0.52 g; 1.45 mmol) in 5 ml of dioxane. The reaction mixture is then filtered and the filtrate is evaporated to give 0.32 g (1.39 mmol) of the desired product in the form of a white solid.
Yield: 93%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.72 (3H, s); 2.71 (2H, s); 3.40 (6H, 2s); 3.70 (1H, dd); 3.79 to 3.90 (2H, m); 3.95 (1H, dd); 4.70 (1H, s, exchangeable with D2 O); 5.00 (1H, s broad); 5.20 (1H, s broad).
Elemental analysis: (empirical formula: C11 H18 O5 M=230.26)
______________________________________                                    
               C    H                                                     
______________________________________                                    
% found          57.20  7.89                                              
% calc.          57.38  7.88                                              
______________________________________
Example 33: 5-O-Chloroethylcarbamoyl-1,2-O-isopropylidene-3-isopropenyl-4-O-methyl-.beta.-D-psicopyranose
Following the procedure described for the preparation of Example 3, starting from 1.00 g (3.64 mmol) of the compound obtained in Example 2 and 0.46 ml (0.57 g; 5.40 mmol) of chloroethyl isocyanate, 1.35 g (3.55 mmol) of the desired product in the form of a white-coloured solid are obtained.
Yield: 97%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.30 (3H, s); 1.35 (3H, s); 1.80 (3H, s); 3.25 (3H, s); 3.32 (2H, m); 3.61 (2H, m); 3.72 (1H, d); 3.78 (2H, m); 3.90 (1H, s, exchangeable with D2 O); 3.95 (1H, d); 4.12 (1H, d); 5.08 (1H, s); 5.25 (1H, s broad); 5.28 (1H, s broad); 7.75 (1H, t, exchangeable with D2 O).
Example 34: 5-O-Chloroethylcarbamoyl-1,2-O-isopropylidene-3-(2-methyloxiran-2-yl)-4-O-methyl-β-D-psicopyranose
Following the procedure described for the preparation of Example 4, starting from 0.25 g (0.66 mmol) of the compound obtained in Example 33 and 0.17 g (0.71 mmol) of 72% 3-chloroperbenzoic acid, then purification by chromatography on silica gel (eluant: diethyl ether), 0.16 g (0.40 mmol) of the desired compound in the form of a white-coloured foam is obtained.
Yield: 60%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.40 (9H, s); 2.42 (1H, d); 2.81 (1H, d); 3.30 (5H, s); 3.60 to 3.75 (4H, m, of which 1H exchangeable with D2 O); 3.80 (1H, d); 3.90 (1H, d); 4.20 (1H, d); 5.20 (1H, s broad); 7.60 (1H, t, exchangeable with D2 O).
Elemental analysis: (empirical formula: C16 H26 ClNO8 M=395.84)
______________________________________                                    
          C    H          N      Cl                                       
______________________________________                                    
% found     48.34  6.43       3.68 9.27                                   
% calc.     48.55  6.62       3.54 8.96                                   
______________________________________
Example 35: 5-O-(2,4-Difluorophenylcarbamoyl)-1,2-O-isopropylidene-3-isopropenyl-4-O-methyl-β-D-psicopyranose
Following the procedure described for the preparation of Example 3, starting from 0.50 g (1.82 mmol) of the compound obtained in Example 2 and 0.43 ml (0.56 g; 3.63 mmol) of 2,4-difluorophenyl isocyanate, then purification by chromatography on silica gel (eluant: pentane/diethyl ether, 4:1), 0.75 g (1.75 mmol) of the desired product in the form of a white-coloured solid is obtained.
Yield: 96%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.30 (3H, s); 1.40 (3H, s); 1.85 (3H, s); 3.30 (2H, (3H, s); 3.80 s); 3.82 (1H, d); 4.00 (1H, d); 4.10 (1H, s, exchangeable with D2 O); 4.15 (1H, d); 5.08 (1H, s broad); 5.30 (1H, s broad); 5.40 (1H, s broad); 7.05 (1H, txd); 7.31 (1H, txd); 7.81 (1H, m); 9.70 (1H, s, exchangeable with D2 O).
Example 36: 5-O-(2,4-Difluorophenylcarbamoyl)-1,2-O-isopropylidene-3-(2-methyloxiran-2-yl)-4-O-methyl-β-D-psicopyranose
Following the procedure described for the preparation of Example 4, starting from 0.72 g (1.67 mmol) of the compound obtained in Example 35 and 0.45 g (1.88 mmol) of 72% 3-chloroperbenzoic acid, then purification by chromatography on silica gel (eluant: diethyl ether/petroleum ether, 1:1), 0.32 g (0.72 mmol) of the desired compound in the form of a white-coloured foam is obtained.
Yield: 43%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.40 (9H, s); 2.45 (1H, d); 2.82 (1H, d); 3.36 (3H, s); 3.80 (1H, d); 3.82 (2H, s); 3.95 (1H, s, exchangeable with D2 O); 4.00 (1H, d); 4.25 (1H, d); 5.30 (1H, s broad); 7.05 (1H, txd); 7.30 (1H, txd); 7.80 (1H, m); 9.50 (1H, s, exchangeable with D2 O).
Elemental analysis: (empirical formula: C20 H25 F2 NO8 M=445.42)
______________________________________                                    
         C          H      N                                              
______________________________________                                    
% found    53.65        5.42   3.16                                       
% calc.    53.93        5.66   3.14                                       
______________________________________
Example 37: 5-O-(3-Trifluoromethylphenylcarbamoyl)-1,2-O-isopropylidene-3-(2-methyloxiran-2-yl)-4-O-methyl-β-D-psicopyranose
Following the procedure described for the preparation of Example 3, starting from 0.25 g (0.86 mmol) of the compound obtained in Example 2 and 0.25 ml (0.34 g; 1.82 mmol) of 3-trifluoromethylphenyl isocyanate, then oxidation in accordance with the procedure described in Example 4, and finally purification by chromatography on silica gel (eluant: pentane/ethyl acetate, 4:1), 0.23 g (0.50 mmol) of the desired compound in the form of a white-coloured foam is obtained.
Overall yield: 58%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.40 (9H, s); 2.45 (1H, d); 2.82 (1H, d); 3.40 (3H, s); 3.60 (1H, s, exchangeable with D2 O); 3.80 (3H, d+s); 4.00 (1H, d); 4.25 (1H, d); 5.46 (1H, s broad); 7.32 (1H, d); 7.53 (1H, t); 7.65 (1H, d); 7.92 (1H, s); 10.03 (1H, s, exchangeable with D2 O).
Elemental analysis: (empirical formula: C21 H26 F3 NO8 M=477.43)
______________________________________                                    
         C          H      N                                              
______________________________________                                    
% found    53.33        5.34   3.17                                       
% calc.    52.83        5.49   2.93                                       
______________________________________
Example 38: 5-O-(1-Naphthylcarbamoyl)-1,2-O-isopropylidene-3-(2-methyloxiran-2-yl)-4-O-methyl-β-D-psicopyranose
Following the procedure described for the preparation of Example 3, starting from 0.25 g (0.86 mmol) of the compound obtained in Example 2 and 0.26 ml (0.30 g; 1.79 mmol) of 1-naphthyl isocyanate, then oxidation in accordance with the procedure described in Example 4, and finally purification by chromatography on silica gel (eluant: methylene chloride/ethyl acetate, 4:1), 0.18 g (0.39 mmol) of the desired compound in the form of a white-coloured solid is obtained.
Overall yield: 45%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.42 (9H, s); 2.49 (1tt, d); 2.85 (1H, d); 3.40 (3H, s); 3.85 (4H, m, of which 1H exchangeable with D2 O); 4.00 (1H, d); 4.26 (1H, d); 5.36 (1H, s broad); 7.45 to 7.60 (3H, m); 7.72 (2H, q); 7.95 (1H, m); 8.15 (1H, m); 9.62 (1H, s, exchangeable with D2 O).
Elemental analysis: (empirical formula: C24 H29 NO8 M=459.50)
______________________________________                                    
         C          H      N                                              
______________________________________                                    
% found    62.23        6.30   3.20                                       
% calc.    62.73        6.36   3.05                                       
______________________________________
Example 39: 1,2-O-Isopropylidene-3-O-allyl-β-D-fructopyranose
Step A: 1,2:4,5-di-O-isopropylidene-3-O-allyl-β-D-fructopyranose
10.00 g (38.42 mmol) of 1,2:4,5-di-O-isopropylidene-β-D-fructopyranose, in solution in 20 ml of anhydrous N,N-dimethylformamide, are added dropwise, at room temperature, to a suspension of sodium hydride (60% in oil; 2.30 g; 57.50 mmol) in 60 ml of anhydrous N,N-dimethylformamide. The reaction mixture is stirred at room temperature for 2 hours, and 6.70 ml (9.37 g; 77.45 mmol) of allyl bromide are added dropwise thereto. After 75 minutes' stirring at room temperature, the reaction mixture is poured into 100 ml of an aqueous ammonium chloride solution (10%) cooled to 0° C. Customary treatment of the organic phase and then purification by chromatography on silica gel (eluant: pentane/diethyl ether, 8:1) yield 9.88 g (32.89 mmol) of the desired product in the form of a yellow-coloured oil.
Yield: 85%
Step B: 1,2-O-isopropylidene-3-O-allyl-β-D-fructopyranose
Following the procedure described for the preparation of Example 1, step C, starting from 9.30 g (30.96 mmol) of the compound obtained in the preceding step, then purification by chromatography on silica gel (eluant: ethyl acetate/diethyl ether, 2:1), 6.04 g (23.20 mmol) of the desired product in the form of a white-coloured solid are obtained.
Yield: 75%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.30 (3H, s); 1.35 (3H, s); 3.40 (1H, d); 3.50 (1H, d); 3.65 (2H, m); 3.70 (2H, d); 3.90 (1H, d); 4.03 (1H, dxd); 4.35 (1H, dxd); 4.70 (1H, d, exchangeable with D2 O); 4.82 (1H, d, exchangeable with D2 O); 5.10 (1H, d); 5.25 (1H, d); 5.90 (1H, txdxd).
Example 40: 1,2-O-Isopropylidene-3-O-allyl-4-O-methyl-β-D-fructopyranose
Following the procedure described for the preparation of Example 2, starting from 1.00 g (3.84 mmol) of the compound obtained in Example 39 and 1.91 g of dibutyltin (7.67 mmol) at reflux for 48 hours in 30 ml of methanol and then using the intermediate formed in that reaction and subjecting it to the action of 1.20 ml (2.74 g; 19.27 mmol) of methyl iodide at reflux of dioxane (20 ml) for 60 hours, 0.92 g (3.35 mmol) of the desired compound in the form of a white-coloured foam is isolated after chromatography on silica gel (eluant: pentane/ethyl acetate, 2:1).
Yield: 87%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.28 (3H, s); 1.38 (3H, s); 3.30 (3H, s); 3.32 (1H, dxd); 3.52 (2H, d+s); 3.70 (1H, d); 3.80 (1H, d); 3.92 (2H, m); 4.00 (1H, d); 4.28 (1H, dxd); 4.73 (1H, d, exchangeable with D2 O); 5.10 (1H, d); 5.21 (1H, d); 5.90 (1H, txdxd).
Example 41: 1,2-O-Isopropylidene-3-O-[(2SR)-(2:3-epoxypropyl)]-4-O-methyl-β-D-fructopyranose
Following the procedure described for the preparation of Example 4, starting from 1.18 g (4.30 mmol) of the compound obtained in Example 40 and 1.90 g (8.03 mmol) of 72% 3-chloroperbenzoic acid, then purification by chromatography on silica gel (eluant: diethyl ether), 0.53 g (1.82 mmol) of the desired diastereoisomeric mixture is obtained.
Yield: 42% (mixture of the two diastereoisomers)
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.30 (3H, s); 1.40 (3H, s); 2.50 (1H, m); 2.80 (1H, m); 3.10 (1H, m); 3.30 (7H, m); 3.40 (1H, m); 3.70 (2H, m); 3.80 (1H, m); 4.00 (1H, d); 4.70 (1H, d, exchangeable with D2 O).
Example 42: 5-O-Chloroacetylcarbamoyl-1,2-O-isopropylidene-3-[(2S)-(2:3-epoxypropyl)]-4-O-methyl-β-D-fructopyranose and 5-O-Chloroacetylcarbamoyl-1,2-O-isopropylidene-3-[(2R )-(2:3-epoxypropyl)]-4-O-methyl-β-D-fructopyranose ##STR42##
Following the procedure described for the preparation of Example 3, starting from 0.50 g (1.72 mmol) of the mixture of diastereoisomers obtained in Example 41 and 0.25 ml (0.35 g; 2.93 mmol) of chloroacetyl isocyanate, then purification by chromatography (HPLC, Kromasil 100-5C18 column, eluant: acetonitrile/water, 3:7), 0.189 g (0.46 mmol) of the desired diastereoisomer A and 0.164 g (0.40 mmol) of diastereoisomer B, both in the form of a white-coloured foam, are obtained.
Yield: diastereoisomer A: 27 % diastereoisomer B: 23%
Spectral characteristics Diastereoisomer A:
1 H NMR (DMSO) δ(ppm): 1.32 (3H, s); 1.40 (3H, s); 2.54 (1H, dxd); 2.72 (1H, t); 3.10 (1H, txd); 3.28 (3H, s); 3.29 (1H, m); 3.50 (1H, d); 3.60 (1H, dxd); 3.70 (1H, dxd); 3.85 (2H, d+s); 4.05 (2H, d+s); 4.41 (2H, s); 5.29 (1H, s broad); 11.01 (1H, s, exchangeable with D2 O).
Spectral characteristics Diastereoisomer B:
1 H NMR (DMSO) δ(ppm): 1.32 (3H, s); 1.41 (3H, s); 2.60 (1H, m); 2.70 (1H, m); 3.10 (1H, m); 3.29 (3H, s); 3.50 (1H, d); 3.58 (1H, dxd); 3.70 (1H, dxd); 3.70 to 3.75 (2H, m); 3.80 to 3.85 (2H, m); 4.10 (1H, d); 4.42 (2H, s); 5.25 (1H, s broad); 11.00 (1H, s, exchangeable with D2 O).
Elemental analysis: (empirical formula: C16 H24 ClNO9 M=409.82)
______________________________________                                    
               C     H       N       Cl                                   
______________________________________                                    
            % calc.  46.89   5.90  3.42  8.65                             
Diastereoisomer A                                                         
            % found  46.85   5.90  3.27  8.83                             
Diastereoisomer B                                                         
            % found  47.33   5.96  3.32  8.59                             
______________________________________
Example 43: 1,2-O-Isopropylidene-3-(5-methylhex-1-enyl-β-D-psicopyranose
Step A: 1,2:4,5-di-O-isopropylidene-3-(5-methylhex-1-enyl)-β-D-psicopyranose
18 ml of n-butyllithium (2.5 molar in hexane, i.e. 45.00 mmol) are added dropwise, under a nitrogen atmosphere, to a solution, cooled to -78° C., of 6.55 ml of 5-methylhex-1-yne (4.83 g; 50.26 mmol) in 30 ml of anhydrous tetrahydrofuran. The whole is stirred at -78° C. for 15 minutes and then at 0° C. for 30 minutes. The solution is then added dropwise to a solution, cooled to -78° C., of 1,2:4,5-di-O-isopropylidene-β-D-erythro-2,3-hexodiulo-2,6-pyranose (described in Example 1, step A; 6.50 g; 25.17 mmol) in 140 ml of anhydrous toluene. After 2 hours' stirring at -78° C., the reaction mixture is poured into a 10% aqueous ammonium chloride solution (150 ml) cooled to 0° C. Customary treatment of the organic phase yields 8.60 g of 1,2:4,5-di-O-isopropylidene-3-(5-methylhex-1-ynyl)-β-D-psicopyranose in the form of an oily residue, which is used for the following step without being purified. Hydrogenation of a solution of 3.07 g (8.66 mmol) of that compound in 120 ml of benzene in the presence of 0.82 g of Lindlar catalyst for 1.5 hours yields, after filtration, evaporation and chromatography on silica gel (eluant: pentane/ethyl acetate, 20:1), the desired compound (2.41 g; 6.76 mmol) in the form of a colourless oil.
Yield: 75%
Step B: 1,2-O-isopropylidene-3-(5-methylhex-1-enyl)-β-D-psicopyranose
Following the procedure described for the preparation of Example 1 (step C), starting from 2.25 g (6.31 mmol) of the compound obtained in the preceding step, then evaporation of the 25 ml of acetic acid/water mixture, 4:1, 1.98 g (6.26 mmol) of the desired product in the form of a colourless oil are obtained.
Yield: 99%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 0.85 (6H, d); 1.20 (2H, m); 1.30 (3H, s); 1.40 (3H, s); 1.51 (1H, o); 2.40 (2H, txd); 3.50 (1H, dxd); 3.68 (1H, dxd); 3.81 (3H, m); 4.00 (1H, d); 4.58 (1H, d, exchangeable with D2 O); 4.90 (1H, s, exchangeable with D2 O); 5.15 (1H, d); 5.45 (1H, m); 5.75 (1H, d, exchangeable with D2 O).
Example 44: 1,2-O-Isopropylidene-3-(5-methylhex-1-enyl)-4-O-methyl-β-D-psicopyranose
Following the procedure described for the preparation of Example 2, starting from 1.98 g (6.26 mmol) of the compound obtained in Example 43 and 3.15 g of dibutyltin (12.65 mmol) at reflux for 4 hours in 60 ml of methanol, and then using the intermediate formed in that reaction and subjecting it to the action of 6.50 ml (14.82 g; 104.41 mmol) of methyl iodide at reflux of dioxane (50 ml) for 37 hours, and after purification by chromatography on silica gel (eluant: pentane/diethyl ether, 3:1), 1.37 g (4.15 mmol) of the desired compound in the form of a white-coloured foam are obtained.
Yield: 66%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 0.85 (6H, d); 1.18 (2H, m); 1.30 (3H, s); 1.40 (3H, s); 1.50 (1H, o); 2.40 (2H, m); 3.16 (1H, d); 3.30 (3H, s); 3.72 (1H, dxd); 3.82 (2H, m); 3.95 (1H, d); 4.06 (1H, m); 5.15 (1H, s, exchangeable with D2 O); 5.18 (1H, d); 5.45 (1H, m); 5.90 (1H, d, exchangeable with D2 O).
Example 45: 1,2-O-Isopropylidene-3-[(2S,3S)-(3-isopentyloxiran-2-yl)]-4-O-methyl-.beta.-D-psicopyranose and 1,2-O-isopropylidene-3-[(2R,3R)-(3-isopentyloxiran-2-yl)]-4-O-methyl-.beta.-D-psicopyranose ##STR43##
Following the procedure described for the preparation of Example 4, starting from 1.31 g (3.96 mmol) of the compound obtained in Example 44 and 1.71 g (7.23 mmol) of 3-chloroperbenzoic acid, then purification by chromatography on silica gel (eluant: diethyl ether/pentane, 2:1), 0.69 g (1.99 mmol) of diastereoisomer A (Rf=0.30) and 0.36 g (1.04 mmol) of diastereoisomer B (Rf=0.10), both in the form of a white-coloured foam, are obtained.
Yield: diastereoisomer A: 50% diastereoisomer B: 26%
Spectral characteristics Diastereoisomer A:
1 H NMR (DMSO) δ(ppm): 0.85 (6H, d); 1.28 (2H, m); 1.30 (3H, s); 1.40 (3H, s); 1.55 (1H, o); 1.80 (1H, m); 2.00 (1H, m); 2.80 (1H, txd); 2.90 (1H, d); 3.30 (1H, d); 3.35 (3H, s); 3.72 (1H, d); 3.75 (1H, m); 3.82 (1H, d); 4.10 (1H, s broad); 4.40 (1H, d); 4.96 (1H, s, exchangeable with D2 O); 5.93 (1H, d, exchangeable with D2 O).
Spectral characteristics Diastereoisomer B:
1 H NMR (DMSO) δ(ppm): 0.85 (6H, d); 1.30 (2H, m); 1.30 (3H, s); 1.40 (3H, s); 1.55 (1H, o); 1.66 (1H, m); 1.76 (1H, m); 2.72 (1H, m); 2.90 (1H, d); 3.40 (3H, s); 3.45 (1H, d); 3.70 (1H, dxd); 3.80 (1H, dxd); 3.81 (1H, d); 4.02 (1H, m); 4.10 (1H, d); 4.95 (1H, s, exchangeable with D2 O); 5.45 (1H, d, exchangeable with D2 O).
Example 46: 5-O-chloroacetylcarbamoyl-1,2-O-isopropylidene-3-[(2S,3S)-(3-isopentyloxiran-2-yl)]-4-O-methyl-β-D-psicopyranose and 5-O-chloroacetylcarbamoyl-1,2-O-isopropylidene-3-[(2R,3R )-(3-isopentyloxiran-2-yl)]-4-O-methyl-β-D-psicopyranose ##STR44##
Following the procedure described for the preparation of Example 3, starting from 0.144 g (0.41 mmol) of diastereoisomer A obtained in Example 45 and 0.06 ml (0.08 g; 0.70 mmol) of chloroacetyl isocyanate, then purification by chromatography on silica gel (eluant: diethyl ether/pentane, 1:1), 0.175 g (0.37 mmol) of the desired compound in the form of a white-coloured solid is obtained.
Diastereoisomer B is obtained in accordance with the same procedure starting from diastereoisomer B obtained in Example 45.
Yield: diastereoisomer A: 90% diastereoisomer B: 86%
Spectral characteristics Diastereoisomer A:
1 H NMR (DMSO) δ(ppm): 0.85 (6H, d); 1.30 (5H, m); 1.40 (3H, s); 1.55 (1H, o); 1.80 (1H, m); 2.00 (1H, dxdxd); 2.80 (1H, m); 2.95 (1H, d); 3.30 (3H, s); 3.60 (1H, d); 3.80 (1H, d); 3.88 (1H, s, exchangeable with D2 O); 3.98 (1H, d); 4.41 (2H, d); 4.50 (2H, s); 5.30 (1H, s broad); 11.10 (1H, s, exchangeable with D2 O).
Elemental analysis: (empirical formula: C20 H32 ClNO9 M=465.93)
______________________________________                                    
               C     H       N       Cl                                   
______________________________________                                    
Diastereoisomer A                                                         
            % calc.  51.56   6.92  3.01  7.61                             
            % found  51.22   7.01  3.04  7.97                             
Diastereoisomer B                                                         
            % found  51.47   7.00  3.03  8.27                             
______________________________________
Example 47: 5-O-Ethoxycarbonylcarbamoyl-1,2-O-isopropylidene-3-[(2S*,3S*)-3-isopentyloxiran-2-yl)]-4-O-methyl-β-D-psicopyranose
Following the procedure described for the preparation of Example 3, starting from 0.15 g (0.43 mmol) of diastereoisomer A obtained in Example 45 and 0.06 ml (0.08 g; 0.69 mmol) of ethoxycarbonyl isocyanate, then purification by chromatography on silica gel (eluant: pentane/diethyl ether, 1:1), 0.19 g (0.41 mmol) of the desired compound in the form of a white-coloured solid is obtained.
Yield: 95%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 0.86 (6H, d); 1.20 (3H, t); 1.32 (2H, m); 1.33 (3H, s); 1.35 (3H, s); 1.55 (1H, m); 1.70 to 2.10 (1H, m); 2.80 (1H, m); 2.95 (1H, dd); 3.35 (3H, s); 3.56 (1H, d); 3.76 (2H, m); 3.96 (3H, m, of which 1H exchangeable with D2 O); 4.08 (2H, q); 4.43 (1H, d); 5.28 (1H, m); 10.62 (1H, s, exchangeable with D2 O).
Elemental analysis: (empirical formula: C21 H35 NO10 M=461.51)
______________________________________                                    
         C          H      N                                              
______________________________________                                    
% found    54.61        7.52   2.94                                       
% calc.    54.65        7.64   3.03                                       
______________________________________
Example 48: 5-O-Ethyloxycarbonylmethyl-1,2-O-isopropynaene-3-[(2S*,3S*)-isopentyloxiran-2-yl]-4-O-methyl-β-D-psicopyranose
Following the procedure described for the preparation of Example 3, starting from 0.15 g (0.43 mmol) of diastereoisomer A obtained in Example 45 and 0.06 ml (0.08 g; 0.66 mmol) of ethyl isocyanatoacetate, then purification by chromatography on silica gel (eluant: pentane/diethyl ether, 1:1), 0.17 g (0.36 mmol) of the desired compound in the form of a white-coloured solid is obtained.
Yield: 83%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 0.88 (6H, d); 1.21 (3H, t); 1.30 (2H, m); 1.35 (3H, s); 1.42 (3H, s); 1.56 (1H, m); 1.80 (1H, m); 1.95 (1H, m); 2.82 (1H, m); 2.98 (1H, d); 3.32 (3H, s); 3.55 (1H, d); 3.68 (2H, dd, of which 1H exchangeable with D2 O); 3.80 (3H, m); 3.94 (1H, d); 4.10 (2H, q); 4.43 (1H, d); 5.15 (1H, s broad); 7.95 (1H, t, exchangeable with D2 O).
Elemental analysis: (empirical formula: C22 H37 NO10 M=475.54)
______________________________________                                    
         C          H      N                                              
______________________________________                                    
% found    55.50        7.68   2.97                                       
% calc.    55.57        7.84   2.95                                       
______________________________________
Example 49: 5-O-Chloroacetylcarbamoyl-1,2-O-isopropylidene-3-[(2S,3S)-(3-phenylpropyloxiran-2-yl)]-4-O-methyl-β-D-psicopyranose and 5-O-Chloroacetylcarbamoyl-1,2-O-isopropylidene-3-[(2R,3R)-(3-phenylpropyloxiran-2-yl) ]-4-O-methyl-β-D-psicopyranose ##STR45##
These two diastereoisomers am obtained following the procedures described in Examples 43 to 46, replacing 5-methylhex-1-yne in Example 43 with 5-phenylpent-1-yne.
Spectral characteristics Diastereoisomer A:
1 H NMR (DMSO) δ(ppm): 1.35 (3H, s); 1.45 (3H, s); 1.75 (2H, m); 1.90 (1H, m); 2.05 (1H, txd); 2.60 (2H, t); 2.95 (1H, q); 3.00 (1H, s); 3.30 (3H, s); 3.60 (1H, d) 3.80 (2H, m, of which 1 exchangeable with D2 O); 3.90 (1H, s); 4.00 (1H, d); 4.50 (3H, m); 5.30 (1H, s broad); 7.30 (5H, m); 11.01 (1H, s, exchangeable with D2 O).
Spectral characteristics Diastereoisomer B:
1 H NMR (DMSO) δ(ppm): 1.35 (3H, s); 1.45 (3H, s); 1.80 (3H, m); 2.00 (1H, m); 2.65 (2H, t); 2.85 (1H, m); 2.95 (1H, d); 3.35 (3H, s); 3.70 (1H, d); 3.80 (1H, d); 3.85 (1H, s); 4.00 (1H, d); 4.10 (2H, d, of which 1H exchangeable with D2); 4.45 (2H, s); 5.25 (1H, s broad); 7.30 (5H, m); 11.00 (1H, s, exchangeable with D2 O).
Elemental analysis: (empirical formula: C24 H32 ClNO9 M=513.97)
______________________________________                                    
               C     H       N       Cl                                   
______________________________________                                    
Diastereoisomer A                                                         
            % calc.  56.09   6.28  2.73  6.90                             
            % found  56.44   6.29  2.73  6.84                             
Diastereoisomer B                                                         
            % found  56.55   6.49  2.53  6.78                             
______________________________________
Example 50: 5-O-Chloroacetylcarbamoyl-3-desoxy-1,2-O-isopropylidene-3-(3-phenylpropyloxiran-2- yl)-4-O-methyl-β-D-fructopyranose ##STR46##
Step A: 1,2:4,5-di-O-isopropylidene-3-methyloxalyl-3-(5-phenylpent-1-yne)-β-D-fructopyranose
By replacing 5-methylhex-1-yne in Example 43 with 5-phenylpent-1-yne, the desired 1,2:4,5-di-O-isopropylidene-3-(3-phenylpropyloxiran-2-yl)-β-D-psicopyranose (a single isomer) is obtained in a yield of 88% after chromatography on silica gel (eluant: pentane/diethyl ether, 2:1).
To a solution, cooled to -78° C., of 13.72 g (34.08 mmol) of that compound in 250 ml of anhydrous tetrahydrofuran there are added dropwise, under a nitrogen atmosphere, 44 ml of n-butyllithium (1.6 molar in hexane, i.e. 70.40 mmol). The whole is stirred at -78° C. for 1.5 hours, and 9.20 ml (106.6 mmol) of methyloxalyl chloride are introduced dropwise. The reaction mixture is stirred under a nitrogen atmosphere for 1.75 hours and for 30 minutes at room temperature.
The mixture is then poured into a saturated aqueous sodium hydrogen carbonate solution cooled to 0° C. (250 ml). After customary treatment of the organic phase there are obtained 24 g of an oily residue, which is chromatographed on silica gel (eluant: methylene chloride/ethyl acetate, 99:1) to give 10.44 g (21.38 mmol) of the desired product in the form of a colourless oil.
Yield: 54% (2 steps)
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): from 1.10 to 1.50 (12H, 4s); 1.72 (2H, q); 2.28 (2H, t); 2.70 (2H, t); 3.82 (3H, s); 3.90 (2H, m); 4.18 (1H, dd); 4.40 (2H, m); 4.78 (1H, d); 7.20 (3H, m); 7.30 (2H, m).
Step B: 1,2:4,5-di-O-isopropylidene-3-desoxy-3-(5-phenylpent-1-yne)-β-D-fructopyranose
85 mg of 2,2'-azobis-(2-methylpropionitrile) (0.52 mmol) and 1.79 ml (6.65 mmol) of tributyltin hydride are added in succession to a solution of the compound described in step A (2.50 g; 5.11 mmol) in 70 ml of anhydrous toluene. The whole is heated at reflux of the toluene for one hour, and a further 0.25 ml (0.93 mmol) of tributyltin hydride is added. After refluxing for a further one hour, the toluene is evaporated off under reduced pressure and the resulting oily residue is dissolved in 70 ml of diethyl ether. 30 ml of an aqueous potassium fluoride solution (3.6 molar) are added, and then the two phases are separated. After customary treatment of the organic phase there are obtained 4.29 g of an oily residue, which is chromatographed on silica gel (eluant: pentane/ethyl acetate, 15:1) to give 0.62 g (1.60 mmol) of the desired product in the form of a colourless oil.
Yield: 31%
Elemental analysis: (empirical formula: C23 H30 O5 M=386.49)
______________________________________                                    
               C    H                                                     
______________________________________                                    
% found          71.04  7.90                                              
% calc.          71.48  7.82                                              
______________________________________
Step C: 5-O-Chloroacetylcarbamoyl-3-desoxy-1,2-O-isopropylidene-3-(3-phenylpropyloxiran-2-yl)-4-O-methyl-β-D-fructopyranose
Hydrogenation of a solution of 0.62 g (1.60 mmol) of the compound described in step B in 10 ml of benzene in the presence of 0.29 g of Lindlar catalyst for 45 minutes yields, after filtration and evaporation, the desired compound (0.60 g; 1.54 mmol) in the form of a yellow-coloured oil, which is used for the following step without being purified (crude yield: 96%). Following the experimental protocols described in Examples 1 (step C) to 4, starting from the compound described above, there is obtained 5-O-chloroacetylcarbamoyl-3-dehydroxy-1,2-O-isopropylidene-3-[(5'-phenyl)pentyloxiran-1'-yl]-4-methoxy-β-D-fructopyranose in the form of a white-coloured foam.
Elemental analysis: (empirical formula: C24 H32 ClNO8 M=497.97)
______________________________________                                    
          C    H          N      Cl                                       
______________________________________                                    
% found     57.53  6.52       2.78 7.07                                   
% calc.     57.89  6.48       2.81 7.12                                   
______________________________________
Example 51: 3,5-di-O-Chloroacetylcarbamoyl-1,2-O-isopropylidene-3-(3-phenylpropyloxiran-2-yl)-4-O-methyl-β-D-psicopyranose ##STR47##
0.50 ml (5.87 mmol) of chloroacetyl isocyanate is added, at room temperature and under a nitrogen atmosphere, to a solution of 0.61 g (1.19 mmol) of diastereoisomer A of Example 49 in 7 ml of anhydrous tetrahydrofuran. The reaction mixture is heated at reflux of the tetrahydrofuran for 20 hours, and a further 0.20 ml of chloroacetyl isocyanate is added. The whole is again refluxed for 24 hours, and then the reaction solution is poured into 5 ml of ice-water. After one hour's stirring and customary treatment of the organic phase there is obtained an oily residue, which is chromatographed on silica gel (eluant: diethyl ether) to give 0.42 g (0.66 mmol) of the desired product in the form of a white-coloured foam.
Yield: 55%
Elemental analysis: (empirical formula: C27 H34 Cl2 N2 O11 M=633.48)
______________________________________                                    
          C    H          N      Cl                                       
______________________________________                                    
% found     51.82  5.74       4.04 10.88                                  
% calc.     51.19  5.41       4.42 11.19                                  
______________________________________
Example 52: 3,5-di-O-Chloroacetylcarbamoyl-1,2-O-isopropylidene-4-O-methyl-3-(5-phenylpentyl)-β-D-psicopyranose ##STR48##
Following the procedure described for the preparation of Examples 43 and 44, replacing 5-methylhex-1-yne with 5-phenylpent-1-yne, the desired 1,2-O-isopropylidene-3-(5-phenylpent-1-enyl)-4-O-methyl-β-D-psicopyranose is obtained. Hydrogenation of 1.97 g (5.23 mmol) of that compound in the presence of 0.90 g of palladium-on-carbon (10%) in 100 ml of ethyl acetate yields 1,2-O-isopropylidene-3-(5-phenylpentyl)-4-O-methyl-β-D-psicopyranose. That compound (0.55 g; 1.44 mmol) is dissolved in 9 ml of methylene chloride in the presence of 0.27 ml (3.17 mmol) of chloroacetyl isocyanate in accordance with the procedure described for the preparation of Example 3. After chromatography on silica gel (eluant: diethyl ether/pentane, 2:1), 0.74 g (1.19 mmol) of the desired product is obtained in the form of a white-coloured foam.
Yield (last step): 82%
Elemental analysis: (empirical formula: C27 H36 Cl2 N2 O10 M=619.50)
______________________________________                                    
          C    H          N      Cl                                       
______________________________________                                    
% found     52.72  5.88       4.35 11.34                                  
% calc.     52.35  5.86       4.52 11.45                                  
______________________________________
Example 53: 3,5-di-O-Chloroacetylcarbamoyl-3-isopropyl-1,2-O-isopropylidene-4-O-methyl-β-D-psicopyranose ##STR49##
1.00 g of palladium-on-carbon (10%) is added to a solution of 1.35 g (4.92 mmol) of 1,2-O-isopropylidene-3-isopropenyl-4-O-methyl-β-D-psicopyranose (Example 2) in 50 ml of ethyl acetate. The reaction mixture is stirred under a hydrogen atmosphere for 20 hours and is then filtered. After evaporation, the crude product is isolated quantitatively in the form of an oil. That compound (1.35 g; 4.88 mmol) is dissolved in 30 ml of methylene chloride in the presence of 1.25 ml (14.67 mmol) of chloroacetyl isocyanate, in accordance with the procedure described for the preparation of Example 3. After chromatography on silica gel (eluant: pentane/ethyl acetate, 2:1), 1.84 g (3.57 mmol) of the desired product are obtained in the form of a white-coloured foam.
Yield (last step): 73%
Elemental analysis: (empirical formula: C19 H28 Cl2 N2 O10 M=515.34)
______________________________________                                    
          C    H          N      Cl                                       
______________________________________                                    
% found     43.92  5.57       5.25 13.44                                  
% calc.     44.28  5.48       5.44 13.76                                  
______________________________________
Example 54: 3,5-di-O-Chloroacetylcarbamoyl-1,2-O-isopropylidene-3-(2-methyloxiran-2-yl)-4-O-methyl-β-D-fructopyranose ##STR50##
1.55 ml (18.20 mmol) of chloroacetyl isocyanate are added, at room temperature and under a nitrogen atmosphere, to a solution of 1.50 g (3.66 mmol) of the compound described in Example 4 in 15 ml of anhydrous tetrahydrofuran. The reaction mixture is heated at reflux of the tetrahydrofuran for 21 hours, and then the reaction solution is poured into 10 ml of ice-water. After one hour's stirring and customary treatment of the organic phase there is obtained an oily residue, which is subjected to HPLC chromatography on grafted silica gel (RP 18; eluant: acetonitrile/water, 40:60) to give 0.47 g (0.89 mmol) of the desired product in the form of a white-coloured foam.
Yield: 24%
Elemental analysis: (empirical formula: C19 H26 Cl2 N2 O11 M=529.33)
______________________________________                                    
          C    H          N      Cl                                       
______________________________________                                    
% found     42.78  4.84       4.80 16.48                                  
% calc.     42.01  4.85       5.09 16.06                                  
______________________________________
Example 55: 1,2-Carbonate-5-O-chloroacetylcarbamoyl-4-methoxy-3-(5-phenylpentyl)-.beta.-D-psicopyranose ##STR51##
Step A: 1,2-O-isopropylidene-5-O-benzyl-4-O-methyl-3-(5-phenylpent-1-enyl)-β-D-psicopyranose
Following the procedure described for the preparation of Examples 43 and 44, replacing 5-methylhex-1-yne with 5-phenylpent-1-yne, the desired 1,2-O-isopropylidene-3-(5-phenylpent-1-enyl) is obtained. To a solution of 2.01 g (5.31 mmol) of that compound in 10 ml of anhydrous tetrahydrofuran there are added at 0° C. 0.28 g of sodium hydride (60% in oil) and 0.20 g (0.54 mmol) of tetrabutylammonium iodide. After 30 minutes' stirring at 0° C., 0.76 ml (6.39 mmol) of benzyl bromide is added and the reaction mixture is stirred at room temperature for 19 hours.
After customary treatment of the organic phase and chromatography on silica gel (eluant: pentane/diethyl ether, 4:1), 2.30 g (4.91 mmol) of the desired compound in the form of a colourless oil are obtained.
Yield: 92%
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.28 (3H, s); 1.38 (3H, s); 1.60 (2H, m); 2.40 (2H, m); 2.55 (2H, t); 3.30 (3H, s); 3.39 (1H, s broad); 3.75 (1H, dd); 3.82 (1H, d); 3.95 (1H, dd); 4.00 (1H, d); 4.03 (1H, s broad); 4.48 (1H, s, exchangeable with D2 O); 4.61 (1H, d); 4.71 (1H, d); 5.25 (1H, d); 5.52 (1H, m); from 7.10 to 7.40 (10H, m).
Step B: 1,2-carbonate-5-O-benzyl-4-O-methyl-3-(5-phenylpent-1-enyl)-β-D-psicopyranose
Following the procedure described for the preparation of Example 9, starting from 1.75 g (3.73 mmol) of the compound described in the preceding step and 18 g of acidic resin (DOWEX 50X8-100) in 60 ml of a tetrahydrofuran/water mixture, 1:1, 1.19 g (2.77 mmol; 74%) of crude product are obtained in the form of a yellow-coloured oil. To a solution of 1.10 g (2.57 mmol) of that compound in 20 ml of anhydrous tetrahydrofuran there are added in portions of 1.50 g, over a period of 72 hours, while heating at reflux, 5.50 g (33.91 mmol) of N,N-carbonyldiimidazole.
The reaction mixture is subsequently diluted with diethyl ether and then washed with a molar solution of hydrochloric acid. The organic phase is subsequently neutralised with sodium hydrogen carbonate and then dried over magnesium sulfate and evaporated. An oily residue is obtained, which is chromatographed on silica gel (eluant: pentane/diethyl ether, 3:1). 0.80 g (1.77 mmol) of the desired compound in the form of a white foam is obtained.
Yield: 51% (2 steps)
Spectral characteristics:
1 H NMR (DMSO) δ(ppm): 1.61 (2H, m); 2.40 (2H, m); 2.58 (2H, t); 3.45 (3H, s); 3.55 (1H, s); 3.75 (2H, m); 3.80 (1H, m); 4.22 (1H, d); 4.30 (1H, d); 4.55 (2H, s); 5.15 (1H, d); 5.33 (1H, s, exchangeable with D2 O); 5.60 (1H, m); from 7.15 to 7.40 (10H, m).
Step C: 1,2-carbonate-5-O-chloroacetylcarbamoyl-4-O-methyl-3-(5-phenylpentyl)-.beta.-D-psicopyranose
0.40 g of palladium-on-carbon (10%) is added to a solution of 0.70 g (1.55 mmol) of 1,2-carbonate-5-O-benzyl-4-O-methyl-3-(5-phenylpent-1-enyl]-β-D-psicopyranose described in the preceding step in 40 ml of ethyl acetate.
The reaction mixture is stirred under a hydrogen atmosphere for 4 hours and is then filtered. After evaporation, the crude product is isolated quantitatively. That compound (0.48 g; 1.31 mmol) is dissolved in 10 ml of methylene chloride in the presence of 0.39 ml (4.58 mmol) of chloroacetyl isocyanate at 0° C. for 3 hours. After customary treatment of the organic phase and chromatography on silica gel (eluant: heptane/ethyl acetate, 5:2), 0.32 g (0.66 mmol) of the desired compound in the form of a white foam is obtained.
Yield: 50%
Elemental analysis: (empirical formula: C22 H28 ClNO9 M=485.92)
______________________________________                                    
          C    H          N      Cl                                       
______________________________________                                    
% found     54.98  5.85       2.90 7.66                                   
% calc.     54.38  5.81       2.88 7.30                                   
______________________________________
Example 56: 1,2-Carbonate-3,5-di-O-chloroacetylcarbamoyl-4-O-methyl-3-(5-phenylpentyl)-β-D-psicopyranose ##STR52##
0.13 ml (1.53 mmol) of chloroacetyl isocyanate at room temperature is added to a solution of 1,2-carbonate-5-O-chloroacetylcarbamoyl-4-O-methyl-3-(5-phenylpentyl)-.beta.-D-psicopyranose (0.21 g; 0.43 mmol) in 6 ml of anhydrous methylene chloride. The reaction mixture is stirred under a nitrogen atmosphere for 49 hours.
After customary treatment of the organic phase and chromatography on silica gel (eluant: pentane/ethyl acetate, 1:1), 0.22 g (0.36 mmol) of the desired compound in the form of a white foam is obtained.
Yield: 84%
Elemental analysis: (empirical formula: C25 H30 Cl2 N2 O11 M=605.43)
______________________________________                                    
          C    H          N      Cl                                       
______________________________________                                    
% found     49.88  5.01       4.28 11.47                                  
% calc.     49.60  4.99       4.63 11.71                                  
______________________________________
PHARMACOLOGICAL STUDY Example A: Cytotoxicity of the compounds and of the reference products
Three cell lines were used:
- 1 murine leukaemia, L1210,
- 1 human epidermoid carcinoma, A431,
- 1 primary culture of endothelial cells of pig aorta, ECPA.
The cells are cultured in complete RPMI 1640 culture medium containing 10% foetal calf serum, 2 mM glutamine, 50 units/ml of penicillin, 50 μg/ml of streptomycin and 10 mM HEPES (pH=7.4).
The cells are distributed on microplates and exposed to the cytotoxic compounds. The cells are then incubated for 2 days (L1210), 3 days (ECPA) and 4 days (A431). The number of viable cells is then quantified by means of a colorimetric assay, the Microculture Tetrazolium Assay (Carmichael J., DeGraff W. G., Gazdar A. F., Minna J. D. and Mitchell J. R., Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing, Cancer Res., 47, 936-942, (1987)).
The compounds of the present invention exhibited a very considerable cytotoxic effect on the three cell lines.
By way of example, the IC50 s (concentrations of cytotoxic agent that inhibit the proliferation of the treated cells by 50%) are from 3 to 10 times lower than those of fumagillin, depending upon the cell line.
Example B: Inhibition of the neovascularisation of the chorio-allantoid membrane of chicken embryos
This test is carried out using chicken embryos as previously described (Crum R., Szabo S. and Folkman J., Science, (1985), 230, 1375-1378). Fertilised eggs (d0) are incubated at 37° C. An air pocket is created by removing 1 ml of albumin (d3), then a window is cut in the shell (d4) and the vitellary membrane is removed in order to tree the chorio-allantoid membrane (CAM). The test products are dissolved in ethanol and placed on methylcellulose disks, which are dried and placed on the CAM 48 hours later (d6). Between 8 and 16 eggs are used per group. The area around the disk is then examined 48 hours later. The eggs exhibiting an avascular area greater than 4 mm in diameter are counted and the results are expressed as the percentage of eggs having an avascular area. The results obtained are shown in the Table below:
______________________________________                                    
Inhibition of the neovascularisation                                      
of the chlorio-allantoid membrane of chicken embryos                      
(dose 125 nM)                                                             
Example        %                                                          
______________________________________                                    
 3             59 ± 6                                                  
 4             84 ± 4                                                  
 6             51 ± 5                                                  
 8             55                                                         
13             55 ± 3                                                  
17             48 ± 12                                                 
20             59 ± 6                                                  
22             57 ± 12                                                 
42 (Diast. A)  53 ± 13                                                 
46 (Diast. A)  68 ± 12                                                 
46 (Diast. B)  75 ± 13                                                 
49 (Diast. A)  76 ± 7                                                  
49 (Diast. B)  79 ± 7                                                  
50             75 ± 8                                                  
52             88 ± 5                                                  
53             95 ± 5                                                  
55             90                                                         
56             60                                                         
Fumagillin     80                                                         
______________________________________
Example C: Pharmaceutical composition: tablets
Preparation formula for 1000 tablets containing a dose of 50 mg:
______________________________________                                    
compound of Example 49                                                    
                    50 g                                                  
wheat starch        15 g                                                  
corn starch         15 g                                                  
lactose             65 g                                                  
magnesium stearate   2 g                                                  
silica               1 g                                                  
hydroxypropylcellulose                                                    
                     2 g                                                  
______________________________________

Claims (15)

We claim:
1. A compound of formula (I): ##STR53## in which: A - represents --OR6 and B represents --CH2 --X,
- or, together with B and the carbon atom carrying them, A forms an oxygen-containing heterocycle selected from the group consisting of oxirane, 2,2-dimethyl[1,3]dioxolane, and [1,3 ]dioxolan-2-one,
R1 represents ##STR54## in which Y and Z each represent hydrogen or together form a double bond or together form, with the carbon atoms carrying them, an oxirane ring,
and R2 is selected from the group consisting of hydrogen, hydroxy, and --OR9,
or R1 represents ##STR55## in which n is an integer of 1 to 4 inclusive and Y and Z each represent hydrogen or together form a double bond or together form, with the carbon atoms carrying them, an oxirane ring,
and R2 represents hydrogen,
- or R1 represents hydrogen
and R2 represents ##STR56## as defined above, R3 is selected the group consisting of hydrogen, linear or branched optionally substituted alkyl having from 1 to 6 carbon atoms inclusive, optionally substituted benzyl, optionally substituted benzoyl, optionally substituted formyl, linear or branched optionally unsaturated and optionally substituted acyl having from 1 to 6 carbon atoms inclusive, allyl, and optionally mono- or di-substituted carbamoyl,
R4 - either is selected from the group consisting of hydroxy, linear or branched, optionally substituted alkoxy having 1 to 6 carbon atoms inclusive, optionally mono- or di-substituted carbamoyloxy, piperazinylcarbonyloxy substituted in the 4-position by R9, and imidazol-1-ylcarbonyloxy,
and R5 represents hydrogen,
- or, together with R5 and the carbon atom carrying them, forms a carbonyl group,
R6, R7 and R8 are selected, each independently of the others, from the group consisting of hydrogen, linear or branched optionally substituted alkyl having 1 to 6 carbon atoms inclusive, and phenylalkyl in which the phenyl group is optionally substituted and the alkyl group, which is linear or branched and is optionally substituted, has 1 to 6 carbon atoms inclusive,
R9 is selected from the group consisting of hydrogen, linear or branched optionally substituted alkyl having 1 to 6 carbon atoms inclusive, optionally substituted formyl, linear or branched optionally unsaturated and optionally substituted acyl having 1 to 6 carbon atoms inclusive, linear or branched optionally substituted alkoxycarbonyl having 1 to 6 carbon atoms inclusive, optionally substituted benzyl, and optionally mono- or di-substituted carbamoyl, and
X is selected from the group consisting of hydroxy, halogen, optionally substituted phenylsulfonyloxy, and optionally substituted linear or branched alkylsulfonyloxy having 1 to 6 carbon atoms inclusive,
its optical or geometrical isomers, in pure form or in the form of a mixture, or its pharmaceutically-acceptable addition salts with an acid,
wherein:
- the term "optionally mono- or di-substituted" associated with the above-defined carbamoyl and carbamoyloxy radicals indicates that one or both of the hydrogen atoms carried by the nitrogen atom may be substituted (independently of each other when both hydrogen atoms are substituted) by:
- linear or branched optionally substituted radical having from 1 to 6 carbon atoms inclusive,
- optionally substituted formyl,
- linear or branched, optionally unsaturated and optionally substituted acyl having 1 to 6 carbon atoms inclusive,
- optionally substituted benzoyl,
- optionally substituted phenyl,
- optionally substituted naphthyl, and
- amino optionally substituted by one or two alkyl having 1 to 6 carbon atoms inclusive in a straight or branched chain, each alkyl being optionally substituted,
- the term "optionally substituted" associated with alkyl, alkoxy, alkoxycarbonyl, formyl, acyl, benzyl, benzoyl, phenyl and naphthyl indicates that those radicals may be substituted by one or more chemical entities selected from hydroxy, halogen, trihalomethyl, amino, alkylamino, dialkylamino, linear or branched alkoxy having 1 to 6 carbon atoms inclusive, linear or branched alkoxycarbonyl having 1 to 6 carbon atoms inclusive, and linear or branched acyl having 1 to 6 carbon atoms inclusive,
- the term "optionally substituted" associated with alkylsulfonyloxy and phenylsulfonyloxy indicates that those radicals may be substituted by one or more linear or branched alkyl having 1 to 6 carbon atoms inclusive, and
- the term "unsaturated acyl" is to be understood as meaning acryloyl or methacryloyl.
2. A compound according to claim 1 in which A and B together form, with the carbon atom carrying them, 2,2-dimethyl[1,3]dioxolane, its optical and geometrical isomers, in pure form or in the form of a mixture, and, its pharmaceutically-acceptable addition salts with an acid.
3. A compound according to claim 1 in which A and B together form, with the carbon atom carrying them, oxirane, its optical and geometrical isomers, in pure form or in the form of a mixture, and, its pharmaceutically-acceptable addition salts with an acid.
4. A compound according to claim 1 which is 5-O-chloroacetylcarbamoyl-1,2-O-isopropylidene-3-(3-phenylpropyloxiran-2-yl)-4-O-methyl-β-D-psicopyranose.
5. A compound according to claim 1 which is 5-O-chloroacetylcarbamoyl-1,2-O-isopropylidene-3-[(2S,3S)-(3-phenylpropyloxiran-2-yl)]-4-O-methyl-β-D-psicopyranose.
6. A compound according to claim 1 which is 5-O-chloroacetylcarbamoyl-1,2-O-isopropylidene-3-[(2R,3R )-(3-phenylpropyloxiran-2-yl)]-4-O-methyl-β-D-psicopyranose.
7. A compound according to claim 1 which is 5-O-chloroacetylcarbamoyl-1,2-O-isopropylidene-3-(2-methyloxiran-2-yl)-4-O-methyl-β-D-psicopyranose, or an optical isomer thereof.
8. A compound according to claim 1 which is 1-bromo-1-desoxy-3-(2-methyloxiran-2yl)-4-O-methyl-5-O-methylcarbamoyl-.beta.-D-psicopyranose, or an optical isomer thereof.
9. A compound according to claim 1 which is 5-O-{1-[4-((2,3,4-trimethoxybenzyl)piperazinyl)]carbonyl }-1,2-O-isopropylidene-3-(2-methyloxiran-2-yl)-4-O-methyl-β-D-psicopyranose, or an optical isomer thereof.
10. A compound according to claim 1 which is 4,5-di-O-chloroacetylcarbamoyl-1,2-O-isopropylidene-3-(2-methyloxiran-2-yl)-β-D-psicopyranose, or an optical isomer thereof.
11. A compound according to claim 1 which is (3R,6R,7R,8R)-8-isopropenyl-6,7-dimethoxy-1,4-dioxaspiro[2,5]octan-8-ol.
12. A compound according to claim 1 which is 5-O-chloroacetylcarbamoyl-1,2-O-isopropylidene-3-(2:3-epoxypropyl)-4-O-methyl-β-D-fructopyranose, or an optical isomer thereof.
13. A compound according to claim 1 which is 5-O-chloroacetylcarbamoyl-1,2-O-isopropylidene-3-(3-isopentyloxiran-2-yl)-4-O-methyl-β-D-psicopyranose, or an optical isomer thereof.
14. A method for treating a mammal afflicted with a disease requiring an angiogenesis inhibitor compising the step of administering to said mammal an amount of a compound of claim 1 which is effective for alleviation of said disease.
15. A pharmaceutical composition useful as an angiogenesis inhibitor comprising an effective amount of a compound of claim 1, together with a pharmaceutically-acceptable excipient.
US08/521,189 1994-08-30 1995-08-30 Tetrahydropyran compounds Expired - Fee Related US5595976A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9410462 1994-08-30
FR9410462A FR2723947B1 (en) 1994-08-31 1994-08-31 NOVEL TETRAHYDROPYRANIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Publications (1)

Publication Number Publication Date
US5595976A true US5595976A (en) 1997-01-21

Family

ID=9466593

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/521,189 Expired - Fee Related US5595976A (en) 1994-08-30 1995-08-30 Tetrahydropyran compounds

Country Status (11)

Country Link
US (1) US5595976A (en)
EP (1) EP0699679A1 (en)
JP (1) JPH0873484A (en)
CN (1) CN1127757A (en)
AU (1) AU689290B2 (en)
CA (1) CA2157156A1 (en)
FI (1) FI954026A7 (en)
FR (1) FR2723947B1 (en)
NO (1) NO953400L (en)
NZ (1) NZ272890A (en)
ZA (1) ZA957322B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090317869A1 (en) * 2008-05-02 2009-12-24 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US9504702B2 (en) 2010-08-05 2016-11-29 Seattle Genetics, Inc. Methods of inhibition of protein fucosylation in vivo using fucose analogs
WO2019094631A1 (en) * 2017-11-08 2019-05-16 Washington University Compounds and methods for treating bacterial infections
US10350228B2 (en) 2012-08-23 2019-07-16 Seattle Genetics, Inc. Treatment of sickle cell disease and inflammatory conditions

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10058645A1 (en) * 2000-11-25 2002-05-29 Clariant Gmbh Use of cyclic sugar ketones as catalysts for peroxygen compounds
JP4726477B2 (en) * 2004-12-15 2011-07-20 独立行政法人理化学研究所 Capping reagents in sugar chain synthesis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017608A (en) * 1973-12-14 1977-04-12 Strategic Medical Research Corporation Therapeutic composition and method of therapeutically treating warm blooded animals therewith

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9116896D0 (en) * 1991-08-06 1991-09-18 Erba Carlo Spa 3-deoxymannosamine derivatives and process for their preparation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017608A (en) * 1973-12-14 1977-04-12 Strategic Medical Research Corporation Therapeutic composition and method of therapeutically treating warm blooded animals therewith

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9816069B2 (en) 2008-05-02 2017-11-14 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2009135181A3 (en) * 2008-05-02 2010-02-25 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US8163551B2 (en) 2008-05-02 2012-04-24 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US8574907B2 (en) 2008-05-02 2013-11-05 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US8993326B2 (en) 2008-05-02 2015-03-31 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US20090317869A1 (en) * 2008-05-02 2009-12-24 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US10443035B2 (en) 2008-05-02 2019-10-15 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US11319526B2 (en) 2008-05-02 2022-05-03 Seagen Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US9504702B2 (en) 2010-08-05 2016-11-29 Seattle Genetics, Inc. Methods of inhibition of protein fucosylation in vivo using fucose analogs
US10342811B2 (en) 2010-08-05 2019-07-09 Seattle Genetics, Inc. Methods of inhibition of protein fucosylation in vivo using fucose analogs
US11033561B2 (en) 2010-08-05 2021-06-15 Seagen Inc. Methods of inhibition of protein fucosylation in vivo using fucose analogs
US10350228B2 (en) 2012-08-23 2019-07-16 Seattle Genetics, Inc. Treatment of sickle cell disease and inflammatory conditions
WO2019094631A1 (en) * 2017-11-08 2019-05-16 Washington University Compounds and methods for treating bacterial infections

Also Published As

Publication number Publication date
NO953400L (en) 1996-03-01
CN1127757A (en) 1996-07-31
EP0699679A1 (en) 1996-03-06
FR2723947B1 (en) 1996-09-27
NO953400D0 (en) 1995-08-30
FI954026A0 (en) 1995-08-28
JPH0873484A (en) 1996-03-19
FR2723947A1 (en) 1996-03-01
CA2157156A1 (en) 1996-03-01
AU689290B2 (en) 1998-03-26
ZA957322B (en) 1996-04-09
AU3034595A (en) 1996-03-14
NZ272890A (en) 1996-08-27
FI954026A7 (en) 1996-03-01

Similar Documents

Publication Publication Date Title
US4359476A (en) Adjacently substituted cycloalkane-amide analgesics
JP3520269B2 (en) Compounds suitable for the synthesis of 2- and 3-amino and azide derivatives of 1,5-iminosugars
US4462992A (en) Nitroimidazole radiosensitizers for hypoxic tumor cells and compositions thereof
AU636076B2 (en) 4-desoxy-4-epipodophyllotoxin derivative or pharmaceutically acceptable salt thereof
CA1316921C (en) Cyclohexane derivative
US5629304A (en) Therapeutic agent for thrombocytopenia and indolocarbazole derivatives
US5595976A (en) Tetrahydropyran compounds
US4673668A (en) Aminonaphthacene derivatives
US4460600A (en) Adjacently substituted ketal derivatives of cycloalkane-amide analgesics
US5648382A (en) Cyclohexane compounds
EP0411912A2 (en) Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders
US4133877A (en) Anthracycline ethers and use therefor
EP0332178B1 (en) 2-cyclopentenone derivatives
EP0410953B1 (en) Piperidine compounds with glycosidase inhibition activity
US4244874A (en) 3,8-Dioxo-scirpen-4β,15-diol esters and their use as antitumor agents
US5595998A (en) Pyrazoloquinolines
US4868204A (en) Mycalamide compounds, compositions thereof and methods of preparation and use
EP0097039A1 (en) 5-(E-2-halovinyl)-2&#39;-deoxyuridine derivatives, processes for their preparation, pharmaceutical compositions containing them, and their use in treating viral infections
US5405948A (en) 1,5-diyne-3-cycloalkene compounds
JPH05163292A (en) Process for producing elsamycin A derivative in which 3&#39;and / or 4&#39;-position hydroxyl groups are chemically modified
JPH023624A (en) Acetylenic ester
JPH0543545A (en) New aza-saccharide derivative
GB1584406A (en) 4-phenylpiperidine derivatives and processes for the production thereof
EP0049144A1 (en) 5-Fluoro uracil derivatives
US5834606A (en) Synthesis of conduritol epoxides and aziridines and methods of using such to synthesize higher disaccharides

Legal Events

Date Code Title Description
AS Assignment

Owner name: ADIR ET COMPAGNIE, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BILLINGTON, DAVID;DOREY, GILBERT;LEON, PASCALE;AND OTHERS;REEL/FRAME:007711/0160

Effective date: 19950809

CC Certificate of correction
REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 20010121

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362